Getein Biotech, Inc.
Add: No.9 Bofu Road, Luhe District, Nanjing, 211505, China
Tel: 86-25-68568508 Email: overseas@getein.com.cn Web: www.getein.com

Document No.: GP-GMSQ-2023121301

Letter of Authorization

To whom it may concern,

We, **Getein Biotech, Inc.** (No.9 Bofu Road, Luhe District, Nanjing, 211505, China), hereby authorize Sanmedico SRL (Address: Republic of Moldova, Chisinau, MD-2059, Petricani street, 88/1, office 10) as our official and non-exclusive distributor for registration, promoting, selling, distributing and providing after-sale services of under-mentioned product in the territory of Moldova only:

FIA8000 Quantitative Immunoassay Analyzer and Reagents

Getein1100 Immunofluorescence Quantitative Analyzer and Reagents

Getein1160 Immunofluorescence Quantitative Analyzer and Reagents

Getein 1600 Immunofluorescence Quantitative Analyzer and Reagents

Sanmedico SRL will comply with the laws and regulations of the countries and regions where they are located in and where they are selling mentioned product.

Sanmedico SRL will carry out marketing efforts to fulfill service and maintenance for above mentioned products and will provide with users benefits of having a local stock of above mentioned products and on-time delivery with every order, supported by a local service in local language.

This authorization starts from **1st Jan, 2024** and will be valid to **31th, December, 2024** .

Getein Biotech, Inc. has the right to terminate the authorization before validity and will inform Sanmedico SRL with 10 days in advance.

基蛋生物科技股份有限公司
GETEIN BIOTECH, INC.

Getein Biotech, Inc.
Seal & Signature

Authority Person Name: **Steven Zhou**
Authority Person Position: **Regional Manager**
Date: **2023.12.13**

Digitally signed by Monastîrschii Viorica
Date: 2024.01.23 10:57:10 EET
Reason: MoldSign Signature
Location: Moldova

Declaration of Conformity

according to Directive 98/79/EC, on in vitro diagnostic medical devices

Maker (Name, Address)	**Getein Biotech, Inc.** No. 9 Bofu Road, Luhe District, Nanjing, 211505, China		
Authorized Representative (Name, Address)	**Lotus Global Co., Ltd** 15 Alexandra Road, London UK, NW8 0DP		
Medical device	Description	:	FIA8000 Quantitative Immunoassay Analyzer Cardiac Troponin I Fast Test Kit One Step Test for NT-proBNP (Colloidal Gold) One Step Test for NT-proBNP/cTnI (Colloidal Gold) One Step Test for CK-MB/cTnI/Myo (Colloidal Gold) One Step Test for hs-CRP+CRP (Colloidal Gold) One Step Test for D-Dimer (Colloidal Gold) One Step Test for PCT (Colloidal Gold) One Step Test for β_2-MG (Colloidal Gold) One Step Test for mAlb (Colloidal Gold) One Step Test for NGAL (Colloidal Gold) One Step Test for CysC (Colloidal Gold) One Step Test for HCG+β (Colloidal Gold) One Step Test for CK-MB/cTnI (Colloidal Gold) One Step Test for CK-MB (Colloidal Gold) One Step Test for HbA1c (Colloidal Gold) One Step Test for TSH (Colloidal Gold) One Step Test for TSH/T3/T4 (Colloidal Gold)
	Classification of products according to directive	:	Others
	Batch/serial No. type，production term (if applicable)	:	
Applicable coordination standards:	EN ISO 14971:2012 EN 980:2008 EN-ISO 18113-2:2011 EN ISO 18113-2:2011 EN-IEC 61326-1:2013 EN-IEC 61326-2-2:2013	EN ISO 23640:2015 EN 13612:2002 EN 1041:2008 EN ISO 18113-3:2011 EN-IEC 61010-1:2010	EN ISO 13485:2016 EN ISO15223-1:2012 EN ISO 18113-1:2011 IEC 61010-2-101:2015

Signatory representative declares herein the above mentioned device meets the basic requirements of the European Parliament and the Council's in vitro diagnostic medical devices directive: 98/79/EC Annex III. This declaration of conformity is based on European Parliament and the Council's 98/79/EC directive Annex III. The compiled technical file and quality system document according to 98/79/EC directive Annex III are testified and the quality system certificate has issued by TÜV Rheinland (Shanghai) Co., Ltd.

General Manager: Enben Su

Nanjing, 15th, June, 2016

(place and date of issue)

(name and signature or equivalent marking of authorized person)

By Royal Charter

Certificate of Registration

QUALITY MANAGEMENT SYSTEM - ISO 13485:2016

This is to certify that:

Getein Biotech, Inc.
No.9 Bofu Road
Luhe District
Nanjing
Jiangsu
211505
China

基蛋生物科技股份有限公司
中国
江苏省
南京市
六合区
沿江工业开发区
博富路9号
邮编：211505

Holds Certificate No: **MD 728432**

and operates a Quality Management System which complies with the requirements of ISO 13485:2016 for the following scope:

Please see scope page.

For and on behalf of BSI:

Graeme Tunbridge, Senior Vice President Medical Devices

Original Registration Date: 2020-05-29
Latest Revision Date: 2023-04-26

Effective Date: 2023-07-26
Expiry Date: 2026-07-25

...making excellence a habit.™

Certificate No: **MD 728432**

Registered Scope:

Design & Development, Manufacture and Distribution of Chemiluminescence Immunoassay, Biochemistry Assay, Point of Care Assay (including Colloidal Gold Assay, Immunofluorescence Assay, Dry Chemistry Assay), PCR Assay and Colloidal Gold self-testing Assay to detect infectious disease. Design & Development, Manufacture and Distribution of Analyzers in use of Chemiluminescence Immunoassay, Biochemistry Assay, Point of Care Assay (including Colloidal Gold Assay, Immunofluorescence Assay, Dry Chemistry Assay), PCR Assay to detect infectious disease, Immunofluorescence self-testing Assay to detect dyslipidemia disease, Blood Coagulation Assay to detect thrombotic disease.
研发，生产和销售化学发光法试剂，生化试剂，即时诊断（包括胶体金法，免疫荧光法，干式化学法）试剂，传染病相关PCR分子诊断试剂和胶体金自测试剂。 研发，生产和销售用于化学发光法试剂，生化试剂，即时诊断（包括胶体金法，免疫荧光法，干式化学法）试剂，传染病相关PCR分子诊断试剂，血脂异常疾病相关免疫荧光自测试剂，血栓疾病相关血凝试剂配套使用的分析仪。

Original Registration Date: 2020-05-29
Latest Revision Date: 2023-04-26

Effective Date: 2023-07-26
Expiry Date: 2026-07-25

Certificate No: **MD 728432**

Location	Registered Activities
Getein Biotech, Inc. No.9 Bofu Road Luhe District Nanjing Jiangsu 211505 China 基蛋生物科技股份有限公司 中国 江苏省 南京市 六合区 沿江工业开发区 博富路9号 邮编：211505	Design & Development, Manufacture and Distribution of Chemiluminescence Immunoassay, Biochemistry Assay, Point of Care Assay (including Colloidal Gold Assay, Immunofluorescence Assay, Dry Chemistry Assay), PCR Assay and Colloidal Gold self-testing Assay to detect infectious disease. Design & Development, Manufacture and Distribution of Analyzers in use of Chemiluminescence Immunoassay, Biochemistry Assay, Point of Care Assay (including Colloidal Gold Assay, Immunofluorescence Assay, Dry Chemistry Assay), PCR Assay to detect infectious disease, Immunofluorescence self-testing Assay to detect dyslipidemia disease, Blood Coagulation Assay to detect thrombotic disease. 研发，生产和销售化学发光法试剂，生化试剂，即时诊断（包括胶体金法，免疫荧光法，干式化学法）试剂，传染病相关PCR分子诊断试剂和胶体金自测试剂。 研发，生产和销售用于化学发光法试剂，生化试剂，即时诊断（包括胶体金法，免疫荧光法，干式化学法）试剂，传染病相关PCR分子诊断试剂，血脂异常疾病相关免疫荧光自测试剂，血栓疾病相关血凝试剂配套使用的分析仪。
Getein Biotech, Inc. No. 6 KeFeng Road Jiangbei New District Nanjing Jiangsu 211505 China 基蛋生物科技股份有限公司 中国 江苏省 南京 江北新区 科丰路6号 邮编：211505	Manufacture of Chemiluminescence Immunoassay, Biochemistry Assay, Point of Care Assay (including Colloidal Gold Assay, Immunofluorescence Assay, Dry Chemistry Assay), Colloidal Gold self-testing Assay to detect infectious disease. Manufacture of Analyzers in use of Chemiluminescence Immunoassay, Biochemistry Assay, Point of Care Assay (including Colloidal Gold Assay, Immunofluorescence Assay, Dry Chemistry Assay), PCR Assay to detect infectious disease, Immunofluorescence self-testing Assay to detect dyslipidemia disease, Blood Coagulation Assay to detect thrombotic disease. 生产化学发光法试剂，生化试剂，即时诊断（包括胶体金法，免疫荧光法，干式化学法）试剂和传染病相关胶体金自测试剂。 生产用于化学发光法试剂，生化试剂，即时诊断（包括胶体金法，免疫荧光法，干式化学法）试剂，传染病相关PCR分子诊断试剂，血脂异常疾病相关免疫荧光自测试剂，血栓疾病相关血凝试剂配套使用的分析仪。

Original Registration Date: 2020-05-29

Effective Date: 2023-07-26

Latest Revision Date: 2023-04-26

Expiry Date: 2026-07-25

Certificate -Bescheinigung

TECO
Medical Instruments
Production+Trading GmbH
web: www.teco-gmbh.com
mail: info@teco-gmbh.com

Dieselstrasse 1
D-84088 Neufahrn/NB
fon: +49 8773 70780 00
fax: +49 8773 70780 29

CERTIFICATE OF TRAINING

Vitalie Goreacii
General manager of
Sanmedico
Chisinau
Republic of Moldava

have participated with success at the training session supervised by TECO GmbH, Germany for following instruments:

Coatron A series

- **Installation**
- **Application**
- **General use, also in combination with TECAM**
- **Maintenance**
- **Troubleshooting**
- **After Sales Service**

Training details:

Supervisor:	Chr. Baumgartner, Director RD of TECO
Device	Coatron A4 + A6, Inhouse Master Device
Place:	Laboratories of TECO
Date:	May 5th 2023

TECO
Dipl.-Ing. Univ.
Christian Baumgartner

Dipl.-Ing. Univ. (TUM)
Christian Baumgartner
Director R&D

IVD Industry
POCT Leading Brand

FIA8000

Quantitative Immunoassay Analyzer

PREMIUM POINT OF CARE SOLUTION



Getein Biotech, Inc.

FIA8000 *Quantitative Immunoassay Analyzer*



Highlights

- **Portable Design** — Small in size (250 x 250 x 120mm); Light in weight (1.8kg)
- **Multiplex Test Items** — Cardiac; Inflammation monitoring; Diabetes mellitus; Fertility; Renal function etc.
- **Easy to Use** — Ready-to-use cassette, one-step test, automatic print, quantitative result
- **Reliable Performance** — CV$\leqslant$1%; r$\geqslant$0.990
- **LIS and HIS Connectivity**

Test Items

CARDIAC	cTnI	NT-proBNP	NT-proBNP/cTnI	CK-MB/cTnI/Myo
	H-FABP	CK-MB/cTnI/H-FABP		
VENOUS THROMBOEMBOLISM	D-Dimer			
INFLAMMATION MONITORING	hs-CRP	PCT		
DIABETES CARE	HbA1c			
FERTILITY	HCG+β			
RENAL FUNCTION	β_2-MG	mAlb	CysC	NGAL

Application Department

The analyzer can be widely applied to clinical departments including Cardiology Dept., Clinical Laboratory, Emergency Dept., ICU, Oncology Dept., Nephrology Dept., Pediatrics Dept., Endocrinology Dept., Gynecology Dept., Respiratory Dept., Gastroenterology Dept., Urology Dept. etc.

Flexible Operation Modes

Inside Mode (Automatic Timing)

Sample dispense

Test card insert

Press "ENT" button

Result printed automatically after reaction

Outside Mode (Manual Timing)

Sample dispense

Timing the reaction manually

Test card insert

Result printed automatically in 5-8s

Technical Data

Assay Method	Lateral Flow Chromatography (Colloidal Gold)	
Test Result	Quantitative	
Language	Chinese/English/German/Spanish/Serbian (French,Russian,Arabic,Vietnamese etc. are under developing)	
Display	5.6 Inch Touch Screen; Resolution 640×480	
Printer	Internal Thermal Printer	
Working Environment	Temperature	+15℃ - 35℃
	Relative humidity	10% - 85%
	Air pressure	70.0kPa - 106.0kPa
Power Supply	AC 100~240V, 50~60 Hz	
Data Storage	10,000 results can be saved	
Dimensions	Height	120mm
	Width	250mm
	Length	250mm
Weight	1.8kg	

FIA8000 Parameters

Cat.#	Test Item	Disease	Measuring Range	Sample	Cut-off Value	Reaction Time
CG 1001	cTnI	Myocardial infarction	0.5~50.0ng/ml	S/P/W.B	0.5ng/ml	15min
CG 1002	NT-proBNP	Heart failure	100~35000pg/ml	S/P/W.B	300pg/ml	15min
CG 1003	hs-CRP	Cardiovascular inflammatory diseases; Inflammatory disorders	0.5~200mg/L	S/P/W.B/ Fingertip blood	3mg/L 10mg/L	90s
CG 1004	NT-proBNP /cTnI	Heart failure; Acute coronary syndrome	100~12000pg/ml 0.5~50.0ng/ml	S/P/W.B	300pg/ml 0.5ng/ml	18min
CG 1005	CK-MB /cTnI /Myo	Myocardial injury	2.5~80.0ng/ml 0.5~50.0ng/ml 30~1000ng/ml	S/P/W.B	5ng/ml 0.5ng/ml 70ng/ml	15 min
CG 1006	D-Dimer	Venous thromboembolism; Pulmonary embolism	0.1~10.0mg/L	P/W.B	0.5mg/L	7min
CG 1007	PCT	Sepsis; Septic shock	0.1~50ng/ml	S/P/W.B	0.1ng/ml	15min
CG 1008	CysC	Early diagnosis of kidney disease; Detection of kidney damage for surgery patients	0.5~10.0mg/L	S/P/W.B	0.51~1.09 mg/L	3min
CG 1009	mAlb	Early diagnosis and evaluation of diabetic nephropathy	10~200mg/L	Urine	20mg/L	3min
CG 1010	NGAL	The best indicator of early renal injury	50~5000ng/ml	S/Urine	Serum:200ng/ml Urine:100ng/ml	3min
CG 1011	β_2 - MG	Kidney damage for diabetic & hypertensive patients	0.5~20.0mg/L	S/P/W.B	0.8~3.0 mg/L	3min
CG 1012	CK-MB /cTnI	Myocardial injury	2.5~80.0ng/ml 0.5~50.0ng/ml	S/P/W.B	5ng/ml 0.5ng/ml	15min
CG 1013	HCG+β	Pregnancy early test	5~10000mIU/ml	S/P/W.B	5.1mIU/ml	10min
CG 1017	HbA1c	Diabetes mellitus	2%~14%	W.B	3.8%~5.8%	3min
CG 1018	CK-MB	Myocardial injury	2.5~80.0ng/ml	S/P/W.B	5ng/ml	15min

Getein Biotech, Inc.

Add: No.9 Bofu Road, Luhe District, Nanjing, 211505, China

Tel:+86-25-68569011;68568508;68588528

Fax:+86-25-68568500

Email:sales@getein.com.cn;tech@getein.com.cn

Http:www.bio-GP.com.cn

CE IVD

One Step Test for CK-MB

(Colloidal Gold)

User Manual Cat.# CG1018

INTENDED USE

One Step Test for CK-MB (Colloidal Gold) is intended for *in vitro* quantitative determination of CK-MB in serum, plasma or whole blood. This test is used as an aid in the clinical diagnosis, prognosis and evaluation of myocardial injury such as Acute Myocardial Infarction (AMI), Unstable Angina, Acute Myocarditis and Acute Coronary Syndrome (ACS).

SUMMARY

Creatine kinases are dimer isozymes composed of two monomer subunits, CK-M (for skeletal muscle derived) and CK-B (for brain derived), which can form all three combinations of monomers: CK-BB, CK-MM, and CK-MB. BB is found primarily in the brain. Skeletal muscles primarily contain the MM isoform, with trace amount of MB (around 1-4% of total CK activity). Cardiac muscles also contain the MM isoform, but higher amount of MB, typically around 20% of total CK activity. CK-MB is a more sensitive marker of myocardial injury than total CK activity, because it has a lower basal level and a much narrower normal range. Medical literatures commonly state that CK-MB levels are elevated in 4 to 6 hours, peak at 10 to 24 hours, and return to normal within 3 to 4 days after an acute myocardial infarction. Classically, an increase of the myocardial-specific enzyme CK-MB is considered as the hallmark of acute myocardial infarction, and increased levels are frequently interpreted by the clinician as objective evidence of myocardial cell damage.

PRINCIPLE

Monoclonal antibody against human CK-MB were conjugated with colloidal gold and another set of anti-human CK-MB monoclonal antibodies were coated on test line. After the sample has been applied to the test strip, the gold-labelled anti-human CK-MB monoclonal antibody will bind with the CK-MB in sample and form marked antigen-antibody complex. This complex moves to the test card detection zone by capillary action. Then marked antigen-antibody complex will be captured on test line by another set of monoclonal antibody against human CK-MB resulting in purplish red streaks appear on the test line. The color intensity of test line increases in proportion to the amount of CK-MB in sample.

Then insert test card into FIA8000 Quantitative Immunoassay Analyzer (hereinafter referred to as FIA8000), the concentrations of CK-MB in sample will be determined and displayed on the screen. The value will be stored in FIA8000 and available for downloading. The result can be easily transmitted to the laboratory or hospital information system.

CONTENTS

A kit contains:

1. Getein CK-MB test card in a sealed pouch with desiccant 25
2. Disposable pipet 25
3. User manual 1
4. SD card 1
5. Whole blood buffer 1

A test card consists of:

A plastic shell and a reagent strip which is composed of a sample pad, a colloidal gold pad (coated with gold-labeled anti-human CK-MB monoclonal antibodies), nitrocellulose membrane with test line (the test line T is coated with another anti-human CK-MB monoclonal antibody, and the control line C is coated with rabbit anti-mouse IgG antibody), absorbent paper and liner.

Whole blood buffer composition:

Phosphate buffered saline, proteins, detergent, preservative, stabilizer.

Note: Do not mix or interchange different batches of kits.

APPLICABLE DEVICE

FIA8000 Quantitative Immunoassay Analyzer

STORAGE AND STABILITY

Store the test card at 4~30℃ with a valid period of 24 months.
Use the test card within 1 hour once the foil pouch is opened.
Store the whole blood buffer at 0~30℃ with a valid period of 24 months.
Store the whole blood buffer at 2~8℃ for better results.

PRECAUTIONS

1. For *in vitro* diagnostic use only.
2. For professional use only.
3. Do not use the kit beyond the expiration date.
4. Do not use the test card if the foil pouch is damaged.
5. Do not open pouches until ready to perform the test.
6. Do not reuse the test card.
7. Do not reuse the pipet.
8. Handle all specimens as potentially infectious. Proper handling and disposal methods should be followed in accordance with local regulations.
9. Carefully read and follow user manual to ensure proper test performance.

SPECIMEN COLLECTION AND PREPARATION

1. This test can be used for ***serum, plasma and whole blood samples. Heparin and sodium citrate*** can be used as the anticoagulant for plasma and whole blood. Samples should be free of hemolysis.
2. Suggest using serum or plasma for better results.
3. Serum or plasma can be used directly. For whole blood sample, one drop of whole blood buffer must be added before testing.
4. If testing will be delayed, serum and plasma samples may be stored up to 7 days at 2~8℃ or stored at -20℃ for 6 months before testing (whole blood sample may be stored up to 3 days at 2~8℃).
5. Refrigerated or frozen sample should reach room temperature and be homogeneous before testing. Avoid multiple freeze-thaw cycles.
6. Do not use heat-inactivated samples.
7. SAMPLE VOLUME: ***120 µl***.

TEST PROCEDURE

1. Collect specimens according to user manual.
2. Test card, sample and reagent should be brought to room temperature before testing.
3. Confirm SD card lot No. in accordance with test kit lot No.. Perform “QC (SD)” calibration when necessary (Details refer to 8.2.1 of FIA8000 User Manual).
4. On the main interface of FIA8000, press "ENT" button to enter testing interface.
5. Remove the test card from the sealed pouch immediately before use. Label the test card with patient or control identification.
6. Put the test card on a clean table, horizontally placed.
7. Using sample transfer pipette, deliver ***120 µl*** of sample (or 4 drops of sample when using disposable pipet) into the sample port on the test card (for whole blood sample, one drop of whole blood buffer must be added after loading 120 µl sample on the test card).
8. ***Reaction time: 15 minutes.*** Insert the test card into FIA8000 and press "ENT" button after reaction time is elapsed. The result will be shown on the screen and printed automatically.

Notes:

1. It is required to perform “QC (SD)” calibration when using a new batch of kits.
2. It is suggested to calibrate once for one batch of kits.
3. Make sure the test card insertion is correct and complete.

TEST RESULTS

Valid: When a purplish-red band appears at the control area (C), use FIA8000 to analyze the test card and get the result.
Invalid: If no colored band appears in the control area (C), the test result is invalid. The test should be repeated and if the same situation happened again, please stop using this batch of products and contact your supplier.

EXPECTED VALUE

The expected normal value for CK-MB was determined by testing samples from 500 apparently healthy individuals. The 99th percentile of the concentration for CK-MB is 5.0 ng/ml. (The probability that value of a normal person below 5.0 ng/ml is 99%.)

It is recommended that each laboratory establish its own expected values for the population it serves.

PERFORMANCE CHARACTERISTICS

Measuring Range	2.5~80.0 ng/ml
Lower Detection Limit	≤ 2.5 ng/ml
Within-Run Precision (n=10)	≤10%
Between-Run Precision	≤15%
Recovery	97.6% (mean)

Method Comparison:

The assay was compared with OLYMPUS AU5400 analyzer and its matching CK-MB test kits with 200 serum samples (83 positive samples and 117 negative samples). The correlation coefficient (r) for CK-MB is 0.983.

LIMITATIONS

1. As with all diagnostic tests, a definitive clinical diagnosis should not be made based on the result of a single test. The test results should be interpreted considering all other test results and clinical information such as clinical signs and symptoms.
2. Samples containing interferents may influence the results. The table below listed the maximum allowance of these potential interferents.

Interferent	Hemoglobin	Triglyceride	Bilirubin
Concentration (Max)	10 g/L	10 g/L	0.2 g/L

REFERENCES

1. Mauro Pantaghini; Undefined International Federation of Clinical Chemistry and Laboratory Medicine (IFCC).Scientific Division Committee on Standardization of Markers of Cardiac Damage. Clin Chem Lab Med, 1998, 36:887~893.
2. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Manage 2004).
3. EN ISO 18113-1:2009 *In vitro* diagnostic medical devices - Information supplied by the manufacturer (labelling) - Part 1: Terms, definitions and general requirements.
4. EN ISO 18113-2:2009 *In vitro* diagnostic medical devices - Information supplied by the manufacturer (labelling) - Part 2: *In vitro* diagnostic reagents for professional use (ISO 18113-2:2009).

DESCRIPTION OF SYMBOLS USED

The following graphical symbols used in or found on One Step Test for CK-MB (Colloidal Gold) are the most common ones appearing on medical devices and their packaging. They are explained in more details in the European Standard EN 980:2008 and International Standard ISO 15223-1:2007.

Key to symbols used			
	Manufacturer		Expiration date
	Do not reuse		Date of manufacture
	Consult instructions for use	LOT	Batch code
	Temperature limitation	IVD	*In vitro* diagnostic medical device
Σ	Sufficient for	EC REP	Authorized representative in the European Community
CE	CE mark		Do not use if package is damaged

Thank you for purchasing One Step Test for CK-MB (Colloidal Gold). Please read this user manual carefully before operating to ensure proper use.

Version: WCG28-DL-S-01

Getein Biotech, Inc.
Add: No.9 Bofu Road, Luhe District, Nanjing, 211505, China
Tel: +86-25-68568508
Fax: +86-25-68568500
E-mail: tech@getein.com.cn
overseas@getein.com.cn
Website: www.bio-GP.com.cn

CE IVD

Cardiac Troponin I Fast Test Kit

User Manual Cat.# CG1001

INTENDED USE

Cardiac Troponin I Fast Test Kit is intended for *in vitro* quantitative determination of cardiac Troponin I (cTnI) in serum, plasma or whole blood. This test is used as an aid in the diagnosis of myocardial injury such as Acute Myocardial Infarction (AMI), Unstable Angina, Acute Myocarditis and Acute Coronary Syndrome (ACS).

SUMMARY

Troponin, a molecular complex that is bound to the thin filament (actin) of striated muscle fibers, acts with intracellular calcium to control the interaction of the thin filament with the thick filament (myosin), thus regulating muscle contraction. Troponin consists of three subunits: T, which connects the troponin complex and tropomyosin (another cardiac muscle regulatory protein); I, which prevents muscle contraction in the absence of calcium; and C, which binds calcium. Cardiac Troponin I (MW 22.5 kDa) and the two skeletal muscle isoforms of Troponin I have considerable amino acid sequence homology, but cTnI contains an additional N-terminal sequence and is highly specific for myocardium.

Clinical studies have demonstrated the release of cTnI into the blood stream within hours following acute myocardial infarctions (AMI) or ischemic damage. Elevated levels of cTnI are detectable in blood within 4 to 6 hours after the onset of chest pain, reaching peak concentrations in approximately 8 to 28 hours, and remain elevated for 3 to 10 days following AMI. Due to the high myocardial specificity and the long duration of elevation, cTnI has become an important marker in the diagnosis and evaluation of patients suspected of having an AMI.

The current guideline of The Joint European Society of Cardiology/American College of Cardiology Committee support the use of cTnI as a preferred marker of myocardial injury. Several major studies have shown that cTnI is also a predictor of cardiac risk in patients with unstable angina. The American College of Cardiology and the American Heart Association's current guidelines recommend using troponin results when making treatment decisions regarding unstable angina and non-ST segment elevation MI (NSTEMI).

PRINCIPLE

The test uses an anti-human cTnI monoclonal antibody conjugated with colloidal gold and another anti-human cTnI monoclonal antibody coated on the test line. After the sample has been applied to the test strip, the gold-labelled anti-human cTnI monoclonal antibody binds with the cTnI in sample and forms a marked antigen-antibody complex. This complex moves to the test card detection zone by capillary action. Then marked antigen-antibody complex is captured on the test line by the anti-human cTnI monoclonal antibody resulting in a purplish red streak appears on the test line. The color intensity of the test line increases in proportion to the amount of cTnI in sample.

Then insert test card into FIA8000 Quantitative Immunoassay Analyzer (hereinafter referred to as FIA8000), the concentration of cTnI in sample will be measured and displayed on the screen. The value will be stored in FIA8000 and available for downloading. The result can be easily transmitted to the laboratory or hospital information system.

CONTENTS

A kit contains:

1. Getein cTnI test card in a sealed pouch with desiccant ····· 25
2. Disposable pipet ····· 25
3. User manual ····· 1
4. SD card ····· 1
5. Whole blood buffer ····· 1

A test card consists of:

A plastic shell and a reagent strip which is composed of a sample pad, a colloid gold pad (coated with gold-labelled anti-human cTnI monoclonal antibody), nitrocellulose membrane (the test line is coated with anti-human cTnI monoclonal antibody, and the control line is coated with rabbit anti-mouse IgG antibody), absorbent paper and liner.

Whole blood buffer composition:

Phosphate buffered saline, proteins, detergent, preservative, stabilizer.

Note: Do not mix or interchange different batches of kits.

APPLICABLE DEVICE

FIA8000 Quantitative Immunoassay Analyzer

STORAGE AND STABILITY

Store the test card at 4~30℃ with a valid period of 24 months.
Use the test card within 1 hour once the foil pouch is opened.
Store the whole blood buffer at 0~30℃ with a valid period of 24 months.
Store the whole blood buffer at 2~8℃ for better results.

PRECAUTIONS

1. For *in vitro* diagnostic use only.
2. For professional use only.
3. Do not use the kit beyond the expiration date.
4. Do not use the test card if the foil pouch is damaged.
5. Do not open pouches until ready to perform the test.
6. Do not reuse the test card.
7. Do not reuse the pipet.
8. Handle all specimens as potentially infectious. Proper handling and disposal methods should be followed in accordance with local regulations.
9. Carefully read and follow user manual to ensure proper test performance.

SPECIMEN COLLECTION AND PREPARATION

1. This test can be used for ***serum, plasma and whole blood samples. Heparin and sodium citrate*** can be used as the anticoagulant for plasma and whole blood. Samples should be free of hemolysis.
2. Suggest using serum or plasma for better results.
3. Serum or plasma can be used directly. For whole blood sample, one drop of whole blood buffer must be added before testing.
4. If testing will be delayed, serum and plasma samples may be stored up to 7 days at 2~8℃ or stored at -20℃ for 6

months before testing (whole blood sample may be stored up to 3 days at 2~8℃).
5. Refrigerated or frozen sample should reach room temperature and be homogeneous before testing. Avoid multiple freeze-thaw cycles.
6. Do not use heat-inactivated samples.
7. SAMPLE VOLUME: ***120 µl***.

TEST PROCEDURE

1. Collect specimens according to user manual.
2. Test card, sample and reagent should be brought to room temperature before testing.
3. Confirm SD card lot No. in accordance with test kit lot No.. Perform "QC (SD)" calibration when necessary (Details refer to 8.2.1 of FIA8000 User Manual).
4. On the main interface of FIA8000, press "ENT" button to enter testing interface.
5. Remove the test card from the sealed pouch immediately before use. Label the test card with patient or control identification.
6. Put the test card on a clean table, horizontally placed.
7. Using sample transfer pipette, deliver ***120 µl*** of sample (or 4 drops of sample when using disposable pipet) into the sample port on the test card (for whole blood sample, one drop of whole blood buffer must be added after loading 120 µl sample on the test card).
8. ***Reaction time: 15 minutes.*** Insert the test card into FIA8000 and press "ENT" button after reaction time is elapsed. The result will be shown on the screen and printed automatically.

Notes:
1. It is required to perform "QC (SD)" calibration when using a new batch of kits.
2. It is suggested to calibrate once for one batch of kits.
3. Make sure the test card insertion is correct and complete.

TEST RESULTS

Valid: When a purplish-red band appears at the control area (C), use FIA8000 to analyze the test card and get the result.
Invalid: If no colored band appears in the control area (C), the test result is invalid. The test should be repeated and if the same situation happened again, please stop using this batch of products and contact your supplier.

EXPECTED VALUE

The expected normal value for cTnI was determined by testing samples from 500 apparently healthy individuals. The 99th percentile of the concentration for cTnI is 0.5 ng/ml. (The probability that value of a normal person below 0.5 ng/ml is 99%.) It is recommended that each laboratory establish its own expected values for the population it serves.

PERFORMANCE CHARACTERISTICS

Measuring Range	0.5~50.0 ng/ml
Lower Detection Limit	≤ 0.5 ng/ml
Within-Run Precision (n=10)	≤10%
Between-Run Precision	≤15%
Recovery	95% (mean)

Method Comparison:
The assay was compared with SIEMENS IMMULITE 2000 and its matching cTnI test kits with 200 serum samples (60 positive samples and 140 negative samples). The correlation coefficient (r) for cTnI is 0.952.

LIMITATIONS

1. As with all diagnostic tests, a definitive clinical diagnosis should not be made based on the result of a single test. The test results should be interpreted considering all other test results and clinical information such as clinical signs and symptoms.
2. Samples containing interferents may influence the results. The table below listed the maximum allowance of these potential interferents.

Interferent	Hemoglobin	Triglyceride	Bilirubin
Concentration (Max)	5 g/L	10 g/L	0.2 g/L

REFERENCES

1. Mauro Pantaghini; Undefined International Federation of Clinical Chemistry and Laboratory Medicine (IFCC).Scientific Division Committee on Standardization of Markers of Cardiac Damage. Clin Chem Lab Med, 1998, 36:887~893.
2. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Manage 2004).
3. EN ISO 18113-1:2009 *In vitro* diagnostic medical devices - Information supplied by the manufacturer (labelling) - Part 1: Terms, definitions and general requirements.
4. EN ISO 18113-2:2009 *In vitro* diagnostic medical devices - Information supplied by the manufacturer (labelling) - Part 2: *In vitro* diagnostic reagents for professional use (ISO 18113-2:2009).

DESCRIPTION OF SYMBOLS USED

The following graphical symbols used in or found on Cardiac Troponin I Fast Test Kit are the most common ones appearing on medical devices and their packaging. They are explained in more details in the European Standard EN 980:2008 and International Standard ISO 15223-1:2007.

Key to symbols used			
	Manufacturer		Expiration date
	Do not reuse		Date of manufacture
	Consult instructions for use	LOT	Batch code
	Temperature limitation	IVD	*In vitro* diagnostic medical device
Σ	Sufficient for	EC REP	Authorized representative in the European Community
CE	CE mark		Do not use if package is damaged

Thank you for purchasing Cardiac Troponin I Fast Test Kit. Please read this user manual carefully before operating to ensure proper use.

Version: WCG02-DL-S-01

Getein Biotech, Inc.
Add: No.9 Bofu Road, Luhe District, Nanjing, 211505, China
Tel: +86-25-68568508
Fax: +86-25-68568500
E-mail: tech@getein.com.cn
overseas@getein.com.cn
Website: www.bio-GP.com.cn

CE IVD

One Step Test for D-Dimer

(Colloidal Gold)

User Manual Cat.# CG1006

IINTENDED USE

One Step Test for D-Dimer (Colloidal Gold) is intended for *in vitro* quantitative determination of D-Dimer in plasma or whole blood. The test is used as an aid in the assessment and evaluation of patients suspected of deep-vein thrombosis or pulmonary embolism.

SUMMARY

Deep-vein thrombosis is a common condition, with a lifetime cumulative incidence of 2 to 5 percent. Untreated deep-vein thrombosis can result in pulmonary embolism, a potentially fatal outcome. Anticoagulant therapy reduces both morbidity and mortality from venous thromboembolism, and early diagnosis is therefore important. Accurate diagnosis of deep-vein thrombosis minimizes the risk of thromboembolic complications and averts the exposure of patients without thrombosis to the risks of anticoagulant therapy.
D-Dimer is a marker of endogenous fibrinolysis and should therefore be detectable in patients with deep-vein thrombosis. In recent years, an increasing number of studies have shown the D-Dimer assay has a high negative predictive value and D-Dimer is a sensitive but nonspecific marker of deep-vein thrombosis. Negative D-Dimer can exclude deep-vein thrombosis and pulmonary embolism.

PRINCIPLE

The test uses an anti-human D-Dimer monoclonal antibody conjugated with colloidal gold and another anti-human D-Dimer monoclonal antibody coated on the test line. After the sample has been applied to the test strip, the gold-labelled anti-human D-Dimer monoclonal antibody binds with the D-Dimer in sample and forms a marked antigen-antibody complex. This complex moves to the test card detection zone by capillary action. Then marked antigen-antibody complex is captured on the test line by the anti-human D-Dimer monoclonal antibody resulting in a purplish red streak appears on the test line. The color intensity of the test line increases in proportion to the amount of D-Dimer in sample.
Then insert test card into FIA8000 Quantitative Immunoassay Analyzer (hereinafter referred to as FIA8000), the concentration of D-Dimer in sample will be measured and displayed on the screen. The value will be stored in FIA8000 and available for downloading. The result can be easily transmitted to the laboratory or hospital information system.

CONTENTS

A kit contains:

1. Getein D-Dimer test card in a sealed pouch with desiccant 25
2. Disposable pipet 25
3. User manual 1
4. SD card 1
5. Sample diluent 25

A test card consists of:
A plastic shell and a reagent strip which is composed of a sample pad, a colloidal gold pad (coated with a gold-labelled anti-human D-Dimer monoclonal antibody), nitrocellulose membrane (the test line is coated with another anti-human D-Dimer monoclonal antibody, and the control line is coated with rabbit anti-mouse IgG antibody), absorbent paper and liner.
Sample diluent composition:
Phosphate buffered saline, proteins, detergent, preservative, stabilizer.

Note: Do not mix or interchange different batches of kits.

APPLICABLE DEVICE

FIA8000 Quantitative Immunoassay Analyzer

STORAGE AND STABILITY

Store the test card at 4~30℃ with a valid period of 24 months.
Use the test card within 1 hour once the foil pouch is opened.
Store the sample diluent at 0~30℃ with a valid period of 24 months.
Store the sample diluent at 2~8℃ for better results.

PRECAUTIONS

1. For *in vitro* diagnostic use only.
2. For professional use only.
3. Do not use the kit beyond the expiration date.
4. Do not use the test card if the foil pouch is damaged.
5. Do not open pouches until ready to perform the test.
6. Do not reuse the test card.
7. Do not reuse the pipet.
8. Handle all specimens as potentially infectious. Proper handling and disposal methods should be followed in accordance with local regulations.
9. Carefully read and follow user manual to ensure proper test performance.

SPECIMEN COLLECTION AND PREPARATION

1. This test can be used for ***plasma and whole blood samples. Sodium citrate*** should be used as the anticoagulant for plasma and whole blood. Samples should be free of hemolysis.
2. Suggest using plasma for better results.
3. If testing will be delayed, plasma sample may be stored up to 3 days at 2~8℃ or stored at -20℃ for 1 months before testing (whole blood sample may be stored up to 3 days at 2~8℃).
4. Refrigerated or frozen sample should reach room temperature and be homogeneous before testing. Avoid multiple freeze-thaw cycles.
5. Do not use heat-inactivated samples.
6. SAMPLE VOLUME: ***120 µl***.

TEST PROCEDURE

1. Collect specimens according to user manual.

2. Test card, sample and reagent should be brought to room temperature before testing.
3. Confirm SD card lot No. in accordance with test kit lot No.. Perform “QC (SD)” calibration when necessary (Details refer to 8.2.1 of FIA8000 User Manual).
4. On the main interface of FIA8000, press "ENT" button to enter testing interface.
5. Remove the test card from the sealed pouch immediately before use. Label the test card with patient or control identification.
6. Put the test card on a clean table, horizontally placed.
7. Using sample transfer pipette, deliver ***120 µl*** of sample into one tube of sample diluent, mix gently and thoroughly. Then drop 120 µl (or 4 drops of sample when using disposable pipet) of sample mixture into the sample port on the test card.
8. ***Reaction time: 7 minutes.*** Insert the test card into FIA8000 and press "ENT" button after reaction time is elapsed. The result will be shown on the screen and printed automatically.

Notes:

1. It is required to perform “QC (SD)” calibration when using a new batch of kits.
2. It is suggested to calibrate once for one batch of kits.
3. Make sure the test card insertion is correct and complete.

TEST RESULTS

Valid: When a purplish-red band appears at the control area (C), use FIA8000 to analyze the test card and get the result.
Invalid: If no colored band appears in the control area (C), the test result is invalid. The test should be repeated and if the same situation happened again, please stop using this batch of products and contact your supplier.

EXPECTED VALUE

The expected normal value for D-Dimer was determined by testing samples from 500 apparently healthy individuals. The 95th percentile of the concentration for D-Dimer is 0.5 mg/L. (The probability that value of a normal person below 0.5 mg/L is 95%.)
It is recommended that each laboratory establish its own expected values for the population it serves.

PERFORMANCE CHARACTERISTICS

Measuring Range	0.1~10.0 mg/L
Lower Detection Limit	≤0.1 mg/L
Within-Run Precision (n=10)	≤10%
Between-Run Precision	≤15%
Recovery	99%

Method Comparison:
The assay was compared with SIEMENS CA-7000 and its matching D-Dimer test kits with 200 plasma samples (60 positive samples and 140 negative samples). The correlation coefficient (r) for D-Dimer is 0.978.

LIMITATIONS

1. As with all diagnostic tests, a definitive clinical diagnosis should not be made based on the result of a single test. The test results should be interpreted considering all other test results and clinical information such as clinical signs and symptoms.
2. Samples containing interferents such as rheumatoid factor, human anti-mouse antibody and heterophile antibody may influence the results. In this case, results of this test should be used in conjunction with clinical findings and other tests. The table below listed the maximum allowance of these potential interferents.

Interferent	Hemoglobin	Triglyceride	Bilirubin
Concentration (Max)	5 g/L	25 g/L	0.1 g/L

REFERENCES

1. Sarig G, Klil-Drori AJ, Chap-Marshak D, Brenner B, Drugan A. Activation of coagulation in amniotic fluid during normal human pregnancy.Thromb Res. 2011 Apr 18.
2. Roldán V, Marín F, Muiña B, Torregrosa JM, Hernández-Romero D, Valdés M, Vicente V, Lip GY. Plasma von Willebrand Factor Levels Are an Independent Risk Factor for Adverse Events Including Mortality and Major Bleeding in Anticoagulated Atrial Fibrillation Patients. J Am Coll Cardiol. 2011 Apr 11.
3. Sakamoto K, Yamamoto Y, Okamatsu H, Okabe M. D-dimer is helpful for differentiating acute aortic dissection and acute pulmonary embolism from acute myocardial infarction. Hellenic J Cardiol. 2011 Mar-Apr; 52(2):123~127.
4. EN ISO 18113-1:2009 *In vitro* diagnostic medical devices - Information supplied by the manufacturer (labelling) - Part 1: Terms, definitions and general requirements.
5. EN ISO 18113-2:2009 *In vitro* diagnostic medical devices - Information supplied by the manufacturer (labelling) - Part 2: *In vitro* diagnostic reagents for professional use (ISO 18113-2:2009).

DESCRIPTION OF SYMBOLS USED

The following graphical symbols used in or found on One Step Test for D-Dimer (Colloidal Gold) are the most common ones appearing on medical devices and their packaging. They are explained in more details in the European Standard EN 980:2008 and International Standard ISO 15223-1:2007.

Key to symbols used			
	Manufacturer		Expiration date
	Do not reuse		Date of manufacture
	Consult instructions for use	LOT	Batch code
	Temperature limitation	IVD	*In vitro* diagnostic medical device
	Sufficient for	EC REP	Authorized representative in the European Community
CE	CE mark		Do not use if package is damaged

Thank you for purchasing One Step Test for D-Dimer (Colloidal Gold). Please read this user manual carefully before operating to ensure proper use.

Version: WCG05-DL-S-01

Getein Biotech, Inc.
Add: No.9 Bofu Road, Luhe District, Nanjing, 211505, China
Tel: +86-25-68568508
Fax: +86-25-68568500
E-mail: tech@getein.com.cn
overseas@getein.com.cn
Website: www.bio-GP.com.cn

and be homogeneous before testing. Avoid multiple freeze-thaw cycles.
5. Do not use heat-inactivated samples.
6. SAMPLE VOLUME: ***10 µl***.

TEST PROCEDURE

1. Collect specimens according to user manual.
2. Test card, sample and reagent should be brought to room temperature before testing.
3. Confirm SD card lot No. in accordance with test kit lot No.. Perform “QC (SD)” calibration when necessary (Details refer to 8.2.1 of FIA8000 User Manual).
4. On the main interface of FIA8000, press "ENT" button to enter testing interface.
5. Remove the test card from the sealed pouch immediately before use. Label the test card with patient or control identification.
6. Put the test card on a clean table, horizontally placed.
7. Using sample transfer pipette, deliver ***10 µl*** of sample into one tube of sample diluent, mix gently and thoroughly. Then drop ***120 µl*** of sample mixture (or 4 drops of sample mixture when using disposable pipet) into the sample port on the test card.
8. ***Reaction time: 90 seconds.*** Insert the test card into FIA8000 and press "ENT" button after reaction time is elapsed. The result will be shown on the screen and printed automatically.

Notes:
1. It is required to perform “QC (SD)” calibration when using a new batch of kits.
2. It is suggested to calibrate once for one batch of kits.
3. Make sure the test card insertion is correct and complete.

TEST RESULTS

Valid: When a purplish-red band appears at the control area (C), use FIA8000 to analyze the test card and get the result.
Invalid: If no colored band appears in the control area (C), the test result is invalid. The test should be repeated and if the same situation happened again, please stop using this batch of products and contact your supplier.

EXPECTED VALUE

hs-CRP: The expected normal value for hs-CRP was determined by testing samples from 500 apparently healthy individuals. The 95th percentile of the concentration for hs-CRP is 3 mg/L. (The probability that hs-CRP value of a normal person below 3 mg/L is 95%.)
CRP: The expected normal value for CRP was determined by testing samples from 500 apparently healthy individuals. The 95th percentile of the concentration for CRP is 10 mg/L. (The probability that CRP value of a normal person below 10 mg/L is 95%.)
It is recommended that each laboratory establish its own expected values for the population it serves.

PERFORMANCE CHARACTERISTICS

Measuring Range	0.5~200 mg/L
Lower Detection Limit	≤0.5 mg/L
Within-Run Precision (n=10)	≤10%
Between-Run Precision	≤15%
Recovery:	
CRP	101% (mean)
hs-CRP	103% (mean)

Method Comparison:
The assay was compared with HITACHI 7600/OLYMPUS AU5400 and its matching hs-CRP test kits with 200 serum samples (61 positive samples and 139 negative samples). The correlation coefficient (r) for hs-CRP+CRP is 0.941.

LIMITATIONS

1. As with all diagnostic tests, a definitive clinical diagnosis should not be made based on the results of a single test. The test results should be interpreted considering all other test results and clinical information such as clinical signs and symptoms.
2. Samples containing interferents may influence the results. The table below listed the maximum allowance of these potential interferents.

Interferent	Hemoglobin	Triglyceride	Bilirubin
Concentration (Max)	5 g/L	10 g/L	0.2 g/L

REFERENCES

1. Danesh J, Whincup P, Wslker M, et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analysis. BJM 2000; 321:199~204.
2. Rifai N, Ridker PM. Proposed cardiovascular risk assessment algorithm using high-sensitivity C-reactive protein and lipid screening. Clin Chem 2001; 47:28~30.
3. EN ISO 18113-1:2009 *In vitro* diagnostic medical devices - Information supplied by the manufacturer (labelling) - Part 1: Terms, definitions and general requirements.
4. EN ISO 18113-2:2009 *In vitro* diagnostic medical devices - Information supplied by the manufacturer (labelling) - Part 2: *In vitro* diagnostic reagents for professional use (ISO 18113-2:2009).

DESCRIPTION OF SYMBOLS USED

The following graphical symbols used in or found on One Step Test for hs-CRP+CRP (Colloidal Gold) are the most common ones appearing on medical devices and their packaging. They are explained in more details in the European Standard EN 980:2008 and International Standard ISO 15223-1:2007.

Key to symbols used			
	Manufacturer		Expiration date
	Do not reuse		Date of manufacture
	Consult instructions for use	LOT	Batch code
	Temperature limitation	IVD	*In vitro* diagnostic medical device
	Sufficient for	EC REP	Authorized representative in the European Community
CE	CE mark		Do not use if package is damaged

Thank you for purchasing One Step Test for hs-CRP+CRP (Colloidal Gold). Please read this user manual carefully before operating to ensure proper use.

Version: WCG07-DL-S-01

Getein Biotech, Inc.
Add: No.9 Bofu Road, Luhe District, Nanjing, 211505, China
Tel: +86-25-68568508
Fax: +86-25-68568500
E-mail: tech@getein.com.cn
overseas@getein.com.cn
Website: www.bio-GP.com.cn

CE IVD

One Step Test for hs-CRP+CRP

(Colloidal Gold)

User Manual Cat.# CG1003

INTENDED USE

One Step Test for hs-CRP+CRP (Colloidal Gold) is intended for in vitro quantitative determination of C-reactive protein (CRP) in serum, plasma, whole blood or fingertip blood. Measurement of CRP is useful for the detection and evaluation of infection, tissue injury and inflammatory disorders. Measurement of high sensitivity CRP (hs-CPR), when used in conjunction with traditional clinical laboratory evaluation of acute coronary syndromes (ACS), may be useful as an independent marker of prognosis for recurrent events in patients with stable coronary disease or ACS.

SUMMARY

C-reactive protein is an acute-phase reactant that precipitated with Pneumococcal C-polysaccharide, and is a non-specific immune response component. CRP has wide distribution in our body, and is an acute-phase protein produced in the liver in response to microbic infection or tissue injury, it measures general levels of inflammation in the body, and the hs-CRP can be used to detect lower concentrations of CRP in serum or plasma. Studies revealed hs-CRP levels seem to be correlated with Atherosclerosis and Acute Myocardial Infarction. And the hs-CRP is an inflammation "marker" for ACS patient and is helpful for primary prevention and risk assessment of cardiovascular disease. Its combination with the ratio of total cholesterol to HDL-C is more accurate than other risk factor in predicting cardiovascular disease.

The American Heart Association and US Centers for Disease Control and Prevention have advocated hs-CRP as a predictor of cardiovascular disease (CVD) to define risk groups: less than 1.0 mg/L indicates low risk, 1.0 to 3.0 mg/L means moderate risk, and the amount above 3.0 mg/L (lower than 10 mg/L) strongly suggests a high risk of CVD. Moreover, higher CRP levels are found in late pregnant women, mild inflammation and viral infections (10-40 mg/L), active inflammation, bacterial infection (40-200 mg/L), severe bacterial infections and burns (>200 mg/L).

PRINCIPLE

The test uses an anti-human CRP monoclonal antibody conjugated with colloidal gold and another anti-human CRP monoclonal antibody coated on the test line. After the sample has been applied to the test strip, the gold-labelled anti-human CRP monoclonal antibody binds with the CRP in sample and forms a marked antigen-antibody complex. This complex moves to the test card detection zone by capillary action. Then marked antigen-antibody complex is captured on the test line by the anti-human CRP monoclonal antibody resulting in a purplish red streak appears on the test line. The color intensity of the test line increases in proportion to the amount of CRP in sample.

Then insert test card into FIA8000 Quantitative Immunoassay Analyzer (hereinafter referred to as FIA8000), the concentration of CRP in sample will be measured and displayed on the screen. The value will be stored in FIA8000 and available for downloading. The result can be easily transmitted to the laboratory or hospital information system.

CONTENTS

A kit contains:

1. Getein hs-CRP+CRP test card in a sealed pouch with desiccant 25
2. Disposable pipet 25
3. User manual 1
4. SD card 1
5. Sample diluent 25

A test card consists of:

A plastic shell and a reagent strip which is composed of a sample pad, a colloidal gold pad (coated with a gold-labelled anti-human CRP monoclonal antibody), nitrocellulose membrane (the test line is coated with another anti-human CRP monoclonal antibody, and the control line is coated with rabbit anti-mouse IgG antibody), absorbent paper and liner.

Sample diluent composition:

Phosphate buffered saline, proteins, detergent, preservative, stabilizer.

Note: Do not mix or interchange different batches of kits.

APPLICABLE DEVICE

FIA8000 Quantitative Immunoassay Analyzer

STORAGE AND STABILITY

Store the test card at 4~30℃ with a valid period of 24 months. Use the test card within 1 hour once the foil pouch is opened.

Store the sample diluent at 0~30℃ with a valid period of 24 months.

Store the sample diluent at 2~8℃ for better results.

PRECAUTIONS

1. For *in vitro* diagnostic use only.
2. For professional use only.
3. Do not use the kit beyond the expiration date.
4. Do not use the test card if the foil pouch is damaged.
5. Do not open pouches until ready to perform the test.
6. Do not reuse the test card.
7. Do not reuse the pipet.
8. Handle all specimens as potentially infectious. Proper handling and disposal methods should be followed in accordance with local regulations.
9. Carefully read and follow user manual to ensure proper test performance.

SPECIMEN COLLECTION AND PREPARATION

1. This test can be used for ***serum, plasma, whole blood and fingertip blood samples. Heparin, sodium citrate and EDTA*** can be used as the anticoagulant for plasma, whole blood and fingertip blood. Samples should be free of hemolysis.
2. Suggest using serum or plasma for better results.
3. If testing will be delayed, serum and plasma samples may be stored up to 7 days at 2~8℃ or stored at -20℃ for 6 months before testing (whole blood sample may be stored up to 3 days at 2~8℃).
4. Refrigerated or frozen sample should reach room temperature

TECO
MEDICAL INSTRUMENTS
PRODUCTION+TRADING GMBH
Dieselstraße 1
D-84088 Neufahrn N.B.
fon: +49-8773/707 80-0
fax: +49-8773/707 80-29

TO WHOM IT MAY CONCERN
To any governmental departments,
registration and/or trade offices in MOLDOVA

Distribution Authorisation Letter

This letter confirms that **Sanmedico**
Mun. Chisinau
Str. Petricani 88/1 of. 10
Republica MOLDOVA

is the **legal, exclusive and sole** representative of **TECO Medical Instruments Production + Trading GmbH, Dieselstr. 1, 84088 Neufahrn NB, Germany,** for the territory of **MOLDOVA** only for all TECO products listed below. **Sanmedico** may participate in public and private tenders, providing sales to all TECO customers in the territory. We as manufacturer certify that our warranty is duly passed to the purchaser through **Sanmedico** for the price, delivery schedules and the specifications of the published literature, catalogues and fully covering the commodities offered.

Sanmedico will provide the following information to TECO GmbH when so required in relation to its market surveillance activities:
Reporting of incidents to TECO must take place within 3 working days
Serial number of the device, exact location of the device and the user.

Validity: January 1st, 2023 to December 31st, 2024

Termination: Confirmation ends automatically on Dec. 31st of 2024 and must be then renewed.

Products:

- Coatron M1 — Semi-automated 1-channel Coagulometer (out of production)
- Coatron M2 — Semi-automated 2-channel Coagulometer (out of production)
- Coatron X Eco — Semi-automated 1-channel Coagulometer
- Coatron X Pro — Semi-automated 2-channel Coagulometer
- Coatron X Top — Semi-automated 4-channel Coagulometer
- Coatron A4 — Fully automated Coagulometer, 4 optic channels
- Coatron A6 — Fully automated Coagulometer, 6 optic channels
- Coatron A6 plus — Fully automated Coagulometer, 6 optic channels

all instruments with complete accessory, consumables and spare parts

- Hemostasis Reagents — Complete product line

This document is signed in Neufahrn, Germany, on January 18th, 2023

TECO Medical Instruments Production+Trading GmbH

Christian Hoetzl

Medical Instruments TECO Production+Trading GmbH

Current issue date:	10 November 2022	Original approval(s):
Expiry date:	9 November 2025	ISO 13485 - 10 November 2022
Certificate identity number:	10479697	

Certificate of Approval

This is to certify that the Management System of:

TECO Medical Instruments, Production + Trading GmbH

Dieselstr. 1, 84088 Neufahrn, Germany

has been approved by LRQA to the following standards:

ISO 13485:2016

Approval number(s): ISO 13485 – 00038268

The scope of this approval is applicable to:

Design, development, manufacturing, storage and sales of coagulation instruments and in-vitro-diagnostic reagents used in the hemostaseology and coagulation.

Paul Graaf

Area Operations Manager, Europe

Issued by: LRQA Limited

UKAS MANAGEMENT SYSTEMS 0001

KONFORMITÄTSERKLÄRUNG
DECLARATION OF CONFORMITY

Doc#200/08-2022

Hersteller / Manufacturer:	**TECO Medical Instruments Production + Trading GmbH**
Adresse / Address:	**Dieselstrasse 1, 84088 Neufahrn, Germany**
Marktakteur / Actor ID SRN:	**DE-MF-000022642** https://ec.europa.eu

Wir erklären hier für die im Anhang A (Seite 2 – 23 IVD Produkte) spezifizierten Produkte dass sie gemäß der Richtlinie für In-vitro-Diagnostika Medizinprodukte 98/79/EC klassifiziert sind als allgemeine IVD.

Diese Konformitätserklärung wird unter der alleinigen Verantwortung des Herstellers i.V.m. Artikel 110 Abs.3 und Abs.4 der Verordnung (EU) 2017/746 und des § 8 Abs.1 des Medizinprodukte-Durchführungsgesetzes, in der jeweils geltenden Fassung, ausgestellt.

Im Falle eigenmächtiger Veränderungen am Produkt oder der nicht bestimmungsgemäßen Verwendung verliert diese Erklärung ihre Gültigkeit.

We declare herewith for the products specified in Annex A (page 2 - 23 IVD products) that they are classified as general IVD according to the In Vitro Diagnostic Medical Devices Directive 98/79/EC.

This declaration of conformity is issued under the sole responsibility of the manufacturer in according to article 110 para.3 and para.4 of Regulation (EU) 217/746 and section 8 para.1 of the Medical Device Law Implementing Act.

In case of unauthorised modifications to the products or un-intended use, this declaration loses its validity.

Sie entsprechen den anwendbaren Anforderungen der Richtlinie:	They meet applicable requirements of:
Richtlinie 98/79/EG über In-vitro-Diagnostika klassifiziert gemäß Artikel 9 als "alle anderen Produkte"	Directive 98/79/EC on in-vitro-diagnostic medical devices classified according to article 9 as „all other products"
Die Qualitätssicherung entspricht den Anforderungen der Richtlinie 98/79/EG über In-vitro-Diagnostika für diese Art von Produkten.	The Quality Assurance is in accordance with the requirements of Directive 98/79/EC on in-vitro-diagnostic medical devices for those kind of products.
Der implementierte QM-Prozess entspricht der EN ISO 13485:2021	The implemented QM Process complies with EN ISO 13485:2021
Die vorstehende Konformitätserklärung ist gültig für alle Chargen dieser Produkte, die nach dem Datum der Unterzeichnung in Verkehr gebracht wurden.	The above mentioned declaration of conformity is valid for all lots of this product, which are distributed after the date of signature.
Das Konformitätsbewertungsverfahren entspricht Anhang III der Richtlinie 98/79/EG über In-vitro-Diagnostika für diese Art von Produkten.	The conformity assessment procedure complies with Annex III of Directive 98/79/EC on in-vitro-diagnostic medical devices for those kind of products.

Ort und Datum der Unterzeichnung:
Place and date of issue: Neufahrn, 2022-08-31

Medical Instruments TECO Production+Trading GmbH

Christian Hötzl
Verantwortliche Person / PRRC

©TECO Medical Instruments Production + Trading GmbH • Dieselstrasse 1 • 84088 Neufahrn i.NB • GERMANY
Fon +49 8773 70780 00 • Fax +49 8773 70780 29 • info@teco-gmbh.com • www.teco-medical.com

Doc#200/08-2022

KONFORMITÄTSERKLÄRUNG – DECLARATION OF CONFORMITY

Directive 98/79/EC Annex A
Übrige Produkte – Reagenzien für In-vitro-Diagnostika
Other products – Reagents for in vitro diagnostic – general IVD

Pos.	Article No	Tradename	Unit	Generic Device Term	EMDN / GMDN Code EUDAMED DI
1	A0230-040	TEClot PT-S (Quick)	10x4ml PT-S	Prothrombin time (quick test)	W0103020101 / 30539 B-PTS-A0230-040X7
2	A0230-100	TEClot PT-S (Quick)	10x10ml PT-S	Prothrombin time (quick test)	W0103020101 / 30539 B-PTS-A0230-100WY
3	A0260-050	TEClot PT-B (Owren)	5x10ml PT-B	Prothrombin time (quick test)	W0103020199 / 55986 B-PTB-A0260-050G2
4	A0320-050	TEClot APTT-S	10x5ml APTT-S	Activated partial thromboplastin time	W0103020102 / 55982 B-APTTS-A0320-050AM
5	A0401-020	TEClot TT	10x2ml TT	Thrombin time / reptilase / batroxbin time	W0103020103 / 55988 B-TT-A0401-0207P
6	A0511-020	TEClot FIB	10x2ml FIB	Fibrinogen assays (factor i)	W0103020201 / 55997 B-FIB-A0511-020N2
7	A0511-050	TEClot FIB	10x5ml FIB	Fibrinogen assays (factor i)	W0103020201 / 55997 B-FIB-A0511-050NB
8	C1010-020	TEChrom AT	6x6ml reagent FXa 3x3 ml substrate	Antithrombin	W0103020602 / 56156 B-AT-C1010-020HL
9	D2010-012	Red D-Dimer	3x4ml latex 3x7ml reaction buffer	D-Dimer	W0103020503 / 47349 B-DD-D2010-0126W
10	D2020-005	Blue D-Dimer LC	1x5ml latex LC 1x7ml reaction buffer	D-Dimer	W0103020503 / 47349 B-DD-D2020-0057E
11	P8001-010	TECal N	10x1ml	Calibration plasma for haemostasis	W0103020701 / 45786 B-CAL-P8001-005X8
12	P8200-005	TECal DD	5x1ml	Calibration plasma for haemostasis	W0103020701 / 47348 B-CAL-P8200-005XX
13	P6001-010	TEControl N	10x1ml	Control plasma for haemostasis	W0103020702 / 30590 B-CTRL-P6001-010H7
14	P6101-010	TEControl A	10x1ml	Control plasma for haemostasis	W0103020702 / 30590 B-CTRL-P6101-010HQ
15	P6201-010	TEControl A Plus	10x1ml	Control plasma for haemostasis	W0103020702 / 30590 B-CTRL-P6201-010J9
16	P5001-010	TEClot Factor II	10x1ml	Coagulation factor ii (prothrombin)	W0103020202 / 30542 B-FAC-II-P5001-010ML
17	P5101-010	TEClot Factor V	10x1ml	Coagulation factor v	W0103020204 / 30544 B-FAC-V-P5101-010AN
18	P5201-010	TEClot Factor VII	10x1ml	Coagulation factor vii	W0103020205 / 30545 B-FAC-VII-P5201-0107B
19	P5301-010	TEClot Factor VIII	10x1ml	Coagulation factor viii	W0103020207 / 30547 B-FAC-VIII-P5301-01097
20	P5401-010	TEClot Factor IX	10x1ml	Coagulation factor ix	W0103020208 / 30548 B-FAC-IX-P5401-0106C
21	P5501-010	TEClot Factor X	10x1ml	Coagulation factor x	W0103020209 / 30549 B-FAC-X-P5501-010EQ
22	P5601-010	TEClot Factor XI	10x1ml	Coagulation factor xi	W0103020210 / 30551 B-FAC-XI-P5601-010A8
23	P5701-010	TEClot Factor XII	10x1ml	Coagulation factor xii	W0103020211 / 30552 B-FAC-XII-P5701-010CJ

(Recital 23 of Directive 98/79/EC on In Vitro Diagnostics Medical Devices) - Annex A - general IVD

©TECO Medical Instruments Production + Trading GmbH • Dieselstrasse 1 • 84088 Neufahrn i.NB • GERMANY
Fon +49 8773 70780 00 • Fax +49 8773 70780 29 • info@teco-gmbh.com • www.teco-medical.com

KONFORMITÄTSERKLÄRUNG
DECLARATION OF CONFORMITY

Doc#001-01/06-2022

Hersteller / Manufacturer: **TECO Medical Instruments Production and Trading GmbH**

Adresse / Address: **Dieselstrasse 1, 84088 Neufahrn, Germany**

Marktakteur / Actor ID SRN: **DE-MF-000022642** https://ec.europa.eu

Die hier benannten Produkte der generischen Produktgruppe erfüllen die Anforderungen der aufgeführten Verordnungen, Richtlinien und Normen. Im Falle eigenmächtiger Veränderungen am Produkt oder der nicht bestimmungsgemäßen Verwendung verliert diese Erklärung ihre Gültigkeit.

Diese Konformitätserklärung wird unter der alleinigen Verantwortung des Herstellers ausgestellt.

BASIS UDI-DI 426018278CMX81152

IVD - halb-automatische Blutgerinnungsmessgeräte - Handelsbezeichnung, Typ, Kat.-Nr.
IVD - semi-automated Coagulation Systems - trade name, type, model, Cat.-No.

Coatron X Eco / Coatron X Pro / Coatron X Top

81 101 10 **81 101 20** **81 101 40**

The products of the generic product group named here fulfil the requirements of listed regulations, directives and standards. In the case of unauthorised modifications to the product or use not in accordance with the intended purpose, this declaration becomes invalid.

This declaration of conformity is issued under the sole responsibility of the manufacturer.

Verordnung (EU) 2017/746
für in-vitro Diagnostika-IVDR
und dem harmonisierten Standard am 2022-05-12:

Risikoklassifizierung gemäß Artikel 47–Anhang VIII
Regel 5 b – „Klasse A "

Konformitätsbewertungsverfahren gemäß:
(EU) 2017/746 Artikel 17 (Anhang II+III)

Angewandte Normen zur Sicherstellung der grundlegenden Anforderungen an Leistung und Sicherheit:

EN ISO 18113-3:2011
DIN EN 62304:2018
DIN EN 62366-1
DIN EN 62366-1:2017
DIN EN 61326-1:2013
DIN EN 55011:2009 + A1:2010
IEC 61010-1:2010, AMD1:2016
IEC 61010-2-101:2015
IEC 61010-1:2010

Richtlinie 2011/65/EU RoHS III
(incl. (EU) 2015/863) - DIN EN IEC 63000

QM-System gemäß (EU) 2017/746 Art.10(8)
angewandter Standard: EN ISO 13485:2021

Regulation (EU) 2017/746
for In-vitro diagnostic medical devices
and it's harmonized standard at 2022-05-12:

Risk classified according to article 47 annex VIII
Rule 5 b – "Class A"

Conformity assessment procedure in accordance with:
(EU) 2017/746 Article 17 (annex II+III)

Standards applied to ensure the essential requirements for performance and safety:

EN ISO 18113-3:2011
DIN EN 62304:2018
DIN EN 62366-1
DIN EN 62366-1:2017
DIN EN 61326-1:2013
DIN EN 55011:2009 + A1:2010
IEC 61010-1:2010, AMD1:2016
IEC 61010-2-101:2015
IEC 61010-1:2010

Directive 2011/65/EU RoHS III
(incl. (EU) 2015/863 - DIN EN IEC 63000

QM-Systems in accordance with (EU) 2017/746 art.10(8)
Applied standard procedure: EN ISO 13485:2021

Ort und Datum der Unterzeichnung:
Place and date of issue: Neufahrn, 2022-06-21

Matthias Dieckmann
General Manager

Medical Instruments TECO Production+Trading GmbH

Christian Hötzl
Verantwortliche Person / PRRC

KONFORMITÄTSERKLÄRUNG

DECLARATION OF CONFORMITY

Doc#100/07-2021

Wir / *We*

TECO Medical Instruments Production and Trading GmbH
Name des Herstellers / Manufacturer's *name*
Dieselstrasse 1, 84088 Neufahrn, Germany
Anschrift / *Address*

erklären in alleiniger Verantwortung, dass die unten gelisteten IVD Zubehör Produkte:
declare under our own responsibility, that the IVD accessories products, listed below:

Doppelküvette / *Double cuvette*	Ref. 19 000 02
Einzelküvette / *Single cuvette*	Ref. 20 000 02, 24 100 00
4-fach Küvette / *Cuvette 4 pos/ea*	Ref. 80 521 10
6-fach Küvette / *Cuvette 6 pos/ea*	Ref. 80 560 00
6-fach Küvette (micro) / *Cuvette 6 pos/ea (micro)*	Ref. 80 570 00

allen anwendbaren Anforderungen folgender Richtlinien entsprechen:

meet all applicable requirements of:

1. Richtlinie 98/79/EG über In-vitro Diagnostika und ihrem Zubehör, klassifiziert gemäß Artikel 9 als: "alle anderen Produkte"- im Sinne von Zubehör zu In vitro Diagnostika gemäß Artikel 1.

1. Directive 98/79/EC on In-vitro diagnostic medical devices and their accessories, classified according to article 9 as: "all other products" – and in term of accessories for in vitro diagnostics according to artivel 1.

2. Richtlinie 2011/65/EU (RoHS III)

2. Directive 2011/65/EU (RoHS III)

Das QM-System des Herstellers ist zertifiziert nach:

The QM-system of the manufacturer is certified for:

EN ISO 13485:2016

EN ISO 13485:2016

Konformitätsbewertungsverfahren gemäß:

Conformity assessment procedure according to:

Gemäß Anhang III der Richtlinie 98/79/EG

According to Annex III of Directive 98/79/EC

Ort und Datum der Unterzeichnung:
Place and date of issue:

Neufahrn, 27.07.2021
Neufahrn, July 27, 2021

Medical Instruments TECO Production+Trading GmbH

Matthias Dieckmann
General Manager

TECO
MEDICAL INSTRUMENTS
PRODUCTION+TRADING GMBH
Dieselstraße 1
D-84088 Neufahrn N.B.
fon: +49-8773/707 80-0
fax: +49-8773/707 80-29

Neufahrn, 26/04/2018

TO WHOM IT MAY CONCERN

We confirm that the instruments Coatron X Eco, Coatron X Pro and Coatron X Top have a closed cuvette system. Cuvettes have to be purchased with voucher identification code from TECO GmbH.

Medical Instruments
TECO
Production+Trading GmbH

Christian Hoetzl
General Manager
TECO Germany

ISO 9001:2008 DEKRA Certification DEKRA certified

Quality Management

We are certified

Voluntary participation in regular monitoring according to ISO 9001:2008

Quality Management EN ISO 13485 www.dekra-iasl.com DEKRA certified

TECO

MEDICAL INSTRUMENTS
PRODUCTION+TRADING GMBH

Dieselstraße 1
D-84088 Neufahrn N.B.
fon: +49-8773/707 80-0
fax: +49-8773/707 80-29

CERTIFICATE

for: **Mr. Vitalie Goreacii**

Company: **Sanmedico SRL**
Str. Petricani 88/1, oficiul 10
Chisinau - Rep. Moldava MD-2059
MOLDOVA

have participated with success at the intensive training session:

Application and technical training for following instruments:

- **Coatron X series**
  - **Installation**
  - **Application**
  - **General use, also in combination with TECAM Software**
  - **Technical and After Sales Service**

Supervisors: Mr. Chr. Hoetzl and Mrs. Wendy Guo

Place of Training: TECO – Germany

Date: November 18th, 2019

Christian Hoetzl
General Manager

TEClot PT-S

CE IVD REF **A0230-010, A0230-040, A0230-100,**

Intended Use
This product is used for the determination of prothrombin time (PT) in plasma according to Quick[1,2]. The test is sensitive to the extrinsic pathway coagulation factors II,V,VII,X and fibrinogen and therefore used for oral anticoagulant therapy with Vitamin-K inhibitors like Warfarin or Marcumar and also for the quantitative determination of extrinsic coagulation factors. The PT measures the extrinsic clotting time (factor VII activation) of test plasma after the addition PT reagent.

Contents & Determinations

Product	TEClot PT-S	TEClot PT-S	TEClot PT-S
Cat.No.	A0230-010	A0230-040	A0230-100
PT-S Reagent*	5x2 mL	10x4 mL	10x10 mL

Determinations

Coatron M**	200 Det.	800 Det.	2000 Det.
Coatron A4	100 Det.	400 Det.	1000 Det.
Coatron A6	200 Det.	800 Det.	2000 Det.

*contains an extract of Rabbit brain with buffer, stabilizers and Calcium chloride.
**Micro method (75µL in total)

Preparation
Reconstitute with high purity water with the volume stated on the vial label.

A0230-010	A0230-040	A0230-100
2 mL	4 mL	10 mL

Let stand at room temperature with occasional swirling for at least 15 min. Then place reagent into instrument and let incubate for further 15 min. The reagent sediments and must be swirled before each testing. On Coatron instruments, you can use a mixing bar for this.

Storage & Stability
Unopened reagents are stable until the expiration date shown on the label stored at 2°-8°C. Opened reagent:

	2-8 °C	20-25 °C	37°C
PT Reagent	5 days	36 hours	8 hours

Precautions
Avoid contact with skin and eyes. Wear suitable protective clothing. Dispose components in compliance with local regulations for infectious material. All components are checked for HIV, HBV, HCV. However products from human blood should be considered as potentially infectious.

Specimen collection and storage[4]
1. Obtain venous blood by clean vein puncture.
2. Immediately mix 9 parts blood with 1 part 3.2% sodium citrate (0.105M) and mix well
3. Centrifuge the specimen at 1500g for 10 min. (platelet < 10000/µL)
4. Separate plasma after centrifugation and store in plastic or siliconised glass tube.
5. Use plasma within 4 hours, otherwise store frozen and thaw just prior to use.

Stability of plasma: 4h at 18-26°C 8h at 2-8° 30d at -20°C 6m at -70°C

Procedure
A. Automated Method: Coatron A

Prothrombin Time		A4		A6	
PAT	Patient	50µl	CP1	25µl	CP1
BUF	IBS Buffer	0µl	P39	0µl	P79
CLR	-	0µl	-	0µl	-
DP	-	0µl	P00	0µl	P00
R0	-	0µl	P00	0µl	P00
R1	-	0µl	P00	0µl	P00
R2	PT Reagent	100µl	P25	50µl	P46

	A4	A6
Incubation	0s	
Maxtime	120s	
Unit	251	
Method	Coag	
Math	log XY	
CT-Mech	No	
Deadtime	7s	

	A4	A6
SENS	2	
POINTS	4	
MIX	No	
Clean	0	0
Multi	1	3
S-Corr	0%	
T-Corr	30% - 4s	

B. Manual Method: Coatron M system
1. Incubate PT reagent at 37°C for at least 10 minutes
2. Pipette **25 µl of sample** into a test cuvette. Incubate at 37°C for 1-2 minutes.
3. Add **50 µl of PT reagent** (37°C) and simultaneously start test.
4. Record the clotting time in seconds.

For other instrument, please refer to your instrument manual for more detailed instrument specific instructions.

Expected Results
Typical seconds: 11 – 18 sec
Normal range: 70 - 130% 0.85 – 1.15 INR

However results are influenced by instruments, technique, calibration etc. Each laboratory is recommended to establish its own range on the specific instrument used.

Standardisation and Calibration
The PT result is expressed as seconds or activity (% Quick) or INR (International Normalised Ratio).

INR results:
were calculated from normal time and ISI value (international sensitivity index). First is obtained by running fresh plasma from a pool of healthy individuals. The ISI value is stated in the LOT specific certificate of analysis.

$$INR = \left(\frac{Patient\ PT}{Normal\ PT}\right)^{ISI}$$

Activity % (Quick) result:
were calcaluted from a calibration curve, which is prepared from reference plasma (e.g. TECAL N) and dilutions in saline solution like 0.9% $NaCl_2$ or TECLOT IBS buffer. At least three or more calibration points are recommended. The calibration curve must be confirmed with control plasma in normal and abnormal range.

% of normal	100%*	50%	25%	12,5%**
diluted in saline	not dil.	1+1	1+3	1+7

* The median of at least 21 healthy individuals is defined as 100%.[5]
**12.5% dilution may cause "+++" results in same cases, because the level of fibrinogen is too high diluted for optical detection.

Quality Control
TEControl or other commercial control plasma should be used for reliable quality control of performance at a frequency in accordance with good laboratory practice (GLP). TEControl can be frozen one time after reconstitution. 120-150 µl stored in closed polypropylen tubes at -20°C is stable for 30 days

Limitations
Great care must be taken to minimize variations which may occur by seemingly insignificant factors.
A. Specimen Collection. AVOID:
1. Use only plastic tubes or siliconised glass.
2. Delayed mixing of blood with anticoagulant.
3. Contamination with tissue thromboplastin.
4. Improper ratio of anticoagulant with blood.
5. Hemolyzed, icteric or lipemic samples may interfere optical systems

B. Laboratory Techniques
1. Perform tests at 37°C.
2. Use only high purity water.
3. Optimum pH is 7.0-7.5.
4. ISI value is not constant within the first 30 min after reconstitution.
5. Reagent sediments and must be swirled before each testing.

Performance Characteristics
Typical performance on instrument Coatron M4

Precision:	CV% (within run)	CV% (inter-runs)
Normal control	< 3,0	< 5,0
Abnormal control	< 3,0	< 5,0

Warranty
This product is warranted to perform in accordance with its labelling and literature. TECO disclaims any implied warranty of merchantability or fitness for any other purpose, and in no event will TECO be liable for any consequential damages arising out of aforesaid express warranty.

References

1. Quick, A.J., The Hemorrhagic Diseases and the Physiology of Hemostasis. Charles C. Thomas: Springfield, IL. 1942.
2. Quick, A.J., Hemorrhagic Diseases. Lea and Febiger: Philadelphia. 1957.
3. Miale, J.B., Laboratory Medicine-Hematology, 4th Edition. C.V. Mosby: St. Louis. 1972.
4. National Committee for Clinical Laboratory Standards: Guidelines for the Standardized Collection, Transport and Preparation of Blood Specimens for Coagulation Testing and Performance of Coagulation Assays.
5. Besselaar A M H P van den, Lewis SM, Mannucci P n Poller L. 1993. Status of present and candidate International Reference Preparations (IRP) of thromboplastin for prothrombin time. Thromb Hemostas 69; 85
6. Besselaar A M H P van den. 1991. The significance of the International Normalized Ratio (INR) for oral anticoagulant therapy. H17CC 3; 146153.

Symbol keys

	Expiry date	IVD	In Vitro Diagnostica		Biological hazard	REF	Catalogue Number	AQUA DEST.	Reconstitute with dest. water		Consult accompanying documents
	Store at 2-8°C	CE	EU conformity		Manufacturer	LOT	Lot. Number		Ready to use	EC REP	Authorized Representative

TECO GmbH, Dieselstr. 1, 84088 Neufahrn NB Germany

Calcium Chloride 0,025M

CE IVD REF ***A0350-050, A0350-100***

Intended Use
This product is used in combination with reagent TEClot APTT-S (Cat.No. A0320) to determine the APTT or also for other 25mM $CaCl_2$ requiring coagulation tests.

Contents & Determinations

Product	Calcium Chloride	Calcium Chloride
Cat.No.	A0350-050	A0350-100
$CaCl_2$ 0.025M	10x5 mL	10x10 mL

Determinations

Coatron M	2000 Det.	4000 Det.
Coatron A	1000 Det.	2000 Det.

Preparation
Ready to use.

Storage and Stability
Unopened reagents are stable until the expiration date shown on the label stored at 2-8°C.

Opened reagent is stable for 30 days at 2-8°C in the original vial.

Precautions
Avoid contact with skin and eyes. Wear suitable protective clothing. Dispose components in compliance with local regulations for infectious material.

Calcium Chloride Solution contains sodium azide. Sodium azide under acid conditions yields Hydrazoic acid, an extremely toxic compound. Azide compounds should be diluted with running water before being discarded. Upon disposal, azide compounds should be flushed with large volumes of water. These precautions are recommended to avoid deposits in metal pipes in which explosive conditions may develop.

Warranty
This product is warranted to perform in accordance with its labelling and literature. TECO disclaims any implied warranty of merchantability or fitness for any other purpose, and in no event will TECO be liable for any consequential damages arising out of aforesaid express warranty.

Symbols key:

	Expiry date	IVD	In Vitro Diagnostica		Biological hazard	REF	Catalogue Number		Consult accompanying documents
	Store at 2-8°C	CE	EU conformity		Manufacturer	LOT	Lot. Number	EC REP	Authorized Representative

Calcium Chloride 0,025M

IVD REF ***A0350-050, A0350-100***

Verwendungszweck
Wird zusammen mit dem Reagenz TEClot APTT-S (Kat. Nr. A0320) zur Bestimmung von der APTT verwendet oder auch für andere Gerinnungstests, für die 25mM CaCl2 benötigt wird.

Inhalt und Bestimmungen

Produkt	Kalzium Chlorid	Kalzium Chlorid
Kat. Nr.	A0350-050	A0350-100
$CaCl_2$ 0.025M	10x5 mL	10x10 mL

Bestimmungen

Coatron M	2000 Det.	4000 Det.
Coatron A	1000 Det.	2000 Det.

Vorbereitung
Das Reagenz ist gebrauchsfertig

Lagerung und Stabilität
Ungeöffnete Reagenzien sind bei einer Lagerung zwischen 2-8°C bis zum auf dem Etikett angegebenen Verfallsdatum haltbar.

Geöffnete Reagenzien sind bei Lagerung zwischen 2-8°C im Originalfläschchen 30 Tage haltbar.

Vorsichtsmaßnahmen
Haut- und Augenkontakt vermeiden. Schutzkleidung tragen. Abfälle unter Beachtung der vorgeschriebenen internationalen, nationalen und lokalen Bestimmungen entsorgen.

Die Calcium Chlorid Lösung enthält Natriumazid. Unter sauren Bedingungen setzt Natriumazid Hyrogenazid frei, ein höchst giftiger Wirkstoff. Azidverbindungen sollten unter laufendem Wasser gelöst werden bevor sie entsorgt werden. Diese Vorsichtsmaßnahmen werden empfohlen, um Ablagerungen in Metallrohren zu verhindern, die explosive Bedingungen entwickeln könnten.

Garantie
Es wird garantiert, dass die Wirkungsweise dieses Produktes den Angaben auf der Packung und in der Produktliteratur entspricht. TECO haftet weder für die Verkäuflichkeit oder Eignung dieses Produktes für irgendwelche andere Zwecke noch für irgendwelche Folgeschäden, die sich aus der vorstehenden, expliziten Garantie ergeben.

Erklärung der Symbole:

	Verfallsdatum	IVD	In-Vitro Diagnostik		Biologische Gefahr	REF	Katalog-Nummer		Begleitpapiere beachten
	Bei 2-8°C lagern	CE	EU Konformität		Hersteller	LOT	Lot. – Nummer	EC REP	Bevollmächtigter

TEClot FIB

IVD REF **A0501-010, A0501-025, A0511-020, A0511-050**

Intended Use

The TEClot FIB is intended for the quantitative determination of fibrinogen in human plasma according to method developed by Clauss.[1] Levels of fibrinogen can increase as a result of inflammation, pregnancy or oral contraceptive use[2]. Decreased levels can be found in certain states such as liver disease and DIC. Congenital deficiencies include afibrinogenaemia (no detectable fibrinogen), hypofibrinogenaemia (<1 mg/ml) and dysfibrinogenaemia (abnormal fibrinogen molecule).

Contents & Preparation

Product	TEClot FIB Kit-10	TEClot FIB Kit-25	TEClot FIB	TEClot FIB
Cat.No.	A0501-010	A0501-025	A0511-020	A0511-050
Thrombin Reagent	5x2 mL	5x5 mL	10x2 mL	10x5 mL
IBS Buffer	1x125 mL	1x125 mL	-	-
TECal Normal	1x1 mL	1x1 mL	-	-
TEControl A	1x1 mL	1x1 mL	-	-

Determinations

Coatron M*	400 Det.	1000 Det.	800 Det.	2000 Det.
Coatron A4	200 Det.	500 Det.	400 Det.	1000 Det.
Coatron A6	200 Det.	500 Det.	400 Det.	1000 Det.

*Micro method (75µL in total)

1. Thrombin Reagent:
   Contains bovine thrombin (~80NIH) with stabilizers
   REF: A0501-010/A0511-020: Reconstitute with 2mL purified water
   REF: A0501-025/A0511-050: Reconstitute with 5mL purified water
2. IBS Buffer: Ready to use. Contains Imidazole buffered saline
3. TECal Normal: Reconstitute with 1 mL purified water. Contains citrated human plasma.
4. TEControl A: Reconstitute with 1 mL purified water. Contains citrated human plasma.

Swirl gently after reconstitution and allow standing for 15 minutes at room temperature. Mix well before use. Do not shake.

Storage & Stability

Unopened reagents are stable until the expiration date shown on the label stored at 2°-8°C. Opened reagent:

Thrombin Reagent*	2-8 °C	15-25 °C	37 °C
	12 days	5 days	24 hours
TEControl or Plasma	2-8 °C	15-25 °C	-20 °C
	8 hours	4 hours	30 days

* Reagent must be protected from UV-light and evaporation

Precautions

Avoid contact with skin and eyes. Wear suitable protective clothing. Dispose components in compliance with local regulations for infectious material.
All components are checked for HIV, HBV, HCV. However products from human blood should be considered as potentially infectious.

Specimen collection and storage[3]

1. Obtain venous blood by clean vein puncture.
2. Immediately mix 9 parts blood with 1 part 3.2% sodium citrate (0.105M) and mix well
3. Centrifuge the specimen at 1500g for 10 min. (platelet < 10000/µL)
4. Separate plasma after centrifugation and store in plastic or siliconised glass tube.
5. Use plasma within 4 hours, otherwise store frozen and thaw just prior to use.

Procedure

A. Automated Method. Coatron A

Fibrinogen		A4		A6	
PAT	Patient	10µl	CP1	10µl	CP1
BUF	IBS Buffer	90µl	P39	90µl	P79
CLR	-	0µl	-	0µl	-
DP	-	0µl	P00	0µl	P00
R0	-	0µl	P00	0µl	P00
R1	-	0µl	P00	0µl	P00
R2	Fibrinogen	50µl	P29	50µl	P49

	A4	A6
Incubation	0s	
Maxtime	120s	
Unit	769	
Method	Coag	
Math	log XY	
CT-Mech	Yes	
Deadtime	3s	

	A4	A6
SENS	0	
POINTS	4	
MIX	No	
Clean	1	3
Multi	1	1
S-Corr	0%	
T-Corr	0%	

B. Manual Method: Coatron M

1. Preparation of Standard, Control and Patient Dilutions

Standard Dilution	Plasma	IBS Buffer
1:5	200µL Standard	800µL
1:10	500µL 1:5 STD	500µL
1:20	500µL 1:10 STD	500µL
1:40	500µL 1:20 STD	500µL
Patient or Control	100µL Plasma	900µL

2. Pipette **50 µl diluted standard or patient plasma** (1:10) into a test cuvette. Prewarm at 37°C for 1-2 minutes.
3. Add **25 µl Thrombin reagent** and simultaneously start test.

For other instrument, please refer to your instrument manual for more detailed instrument specific instructions.

Calibration

TECal Normal or other commercially prepared plasma standard in which Fibrinogen has been determined should be used as reference (200-300mg/dL).
Plot the clotting time obtained with each of the FIB standard dilutions on the y-axis against the concentration of FIB (mg/dL) on the x-axis using log-log graph paper. The line of best fit should be determined by linear regression analysis. The fibrinogen in plasma samples can be determined by interpolation from the calibration curve.

Expected Results

Typical normal results are 180-450 mg/dL[4,5]. However results are influenced by the method of clot detection and can vary from laboratory to laboratory. Each laboratory is recommended to establish its own normal range on the specific instrument used.

Quality Control

TEControl or other commercial control plasma should be used for reliable quality control of performance at a frequency in accordance with good laboratory practice (GLP).). TEControl can be frozen one time after reconstitution. 120-150 µl stored in closed polypropylen tubes at -20°C is stable for 30 days

Limitations

A. Specimen Collection. AVOID:
   1. Use only plastic tubes or siliconised glass.
   2. Delayed mixing of blood with anticoagulant.
   3. Contamination with tissue thromboplastin.
   4. Improper ratio of anticoagulant with blood.
   5. Hemolyzed, icteric or lipemic samples may interfer optical systems

B. Laboratory Techniques
   1. Perform tests at 37°C.
   2. Use only high purity water.
   3. Optimum pH is 7.0-7.5.

Performance Characteristics

Precision:	CV% (within run)	CV% (inter-runs)
Normal control	< 5.0	< 5.0
Abnormal control	< 5.0	< 10.0

(Typical performance on instrument Coatron M4)

Warranty

This product is warranted to perform in accordance with its labelling and literature. TECO disclaims any implied warranty of merchantability or fitness for any other purpose, and in no event will TECO be liable for any consequential damages arising out of aforesaid express warranty.

References

1. Clauss, A., Gerinnungsphysiologische Schnellmethode zur bestimmung des Fibrinogens. Acta Haematol., 1957, 17: 237-246.
2. Shaw, T.S.,Assays for Fibrinogen and its Derivatives, CRC Crit. Rev. Clin. Lab. Sci., 1977, 8: 145-192.
3. National Committee for the National Laboratory (NCCLS) Standards: Collection transport and preparation of blood specimens for coagulation testing and performance of coagulation assays. Document H21-A2, vol. 11, No. 23, 1991.
4. Scully, R.E. et al., Normal Reference Laboratory Values, N. Eng. J. Med., 1980, 302(37) : 37-48.
5. Okuno, T. and Selenko, V., Amer. J. Med. Tech., 1972, 38(6) : 196-201.

Symbols key:

	Expiry date	IVD	In Vitro Diagnostica		Biological hazard	REF	Catalogue Number		Consult accompanying documents
	Store at 2-8°C	CE	EU conformity		Manufacturer	LOT	Lot. Number	EC REP	Authorized Representative

TEClot FIB

IVD REF **A0501-010, A0501-025, A0511-020, A0511-050**

Verwendungszweck

TEClot FIB wird zur quantitativen Bestimmung von Fibrinogen im menschlichen Plasma nach einer von Clauss[1] entwickelten Methode verwendet. Der Fibrinogenpegel kann auf Grund von Entzündungen, Schwangerschaft und dem Gebrauch von Ovulationshemmern ansteigen[2]. Geringere Konzentrationen können bei verschiedenen Krankheiten wie Leberversagen und DIC auftreten. Angeborene Defizite beinhalten Afibrinogenämie (kein auffindbares Fibrinogen), Hypofibrigonämie (<1mg/ml) und Dysfibrinogenämie (abnormale Fibrinogenmoleküle).

Inhalte und Vorbereitungen

Produkt	TEClot FIB Kit-10	TEClot FIB Kit-25	TEClot FIB	TEClot FIB
Kat. Nr.	A0501-010	A0501-025	A0511-020	A0511-050
Thrombin Reagenz	5x2 mL	5x5 mL	10x2 mL	10x5 mL
IBS Puffer	1x125 mL	1x125 mL	-	-
TECal Normal	1x1 mL	1x1 mL	-	-
TEControl A	1x1 mL	1x1 mL	-	-

Bestimmungen

Coatron M*	400 Det.	1000 Det.	800 Det.	2000 Det.
Coatron A4	200 Det.	500 Det.	400 Det.	1000 Det.
Coatron A6	200 Det.	500 Det.	400 Det.	1000 Det.

*Mikromethode (75µL insgesamt)

1. Thrombin Reagenz:
   Enthält Rinderthrombin (~80 NIH) mit Stabilisatoren.
   REF: A0501-010/A0511-020: mit 2ml hochreinem Wasser anlösen
   REF: A0501-025/A0511-050: mit 5ml hochreinem Wasser anlösen
2. IBS Puffer: gebrauchsfertig, 125ml
   Enthält gepufferte Natriumchlorid Lösung, pH 7,3-7,4
3. TECal Normal: Mit 1ml hochreinem Wasser anlösen
   Enthält mit Zitrat versetztes menschliches Plasma.
4. TEControl A: Mit 1ml hochreinem Wasser anlösen
   Enthält mit Zitrat versetztes menschliches Plasma.

Nach der Anlösung vorsichtig leicht schwenken und bei Raumtemperatur 15 Minuten stehen lassen. Vor Gebrauch gut mischen. Nicht schütteln.

Lagerung und Stabilität

Ungeöffnete Reagenzien sind bei Lagerung zwischen 2-8°C bis zum auf dem Etikett angegebenen Verfallsdatum haltbar. **Geöffnete Reagenzien:**

Thrombin Reagenz*	2-8 °C	15-25 °C	37 °C
	12 days	5 days	24 Std
TEControl oder Plasma	2-8 °C	15-25 °C	-20 °C
	8 Std	4 Std	30 Std

* Reagenz muss vor UV-Licht und Verdunstung geschützt werden.

Vorsichtsmaßnahme

Haut- & Augenkontakt vermeiden. Abfälle gemäß lokaler Richtlinien für infektiöse Materialien entsorgen. Alle Bestandteile wurden auf HIV, HBV und HCV getestet. Trotzdem müssen Produkte aus menschlichem Blut immer als potentiell infektiös behandelt werden.

Probenentnahme und Lagerung [3]

1. Venöses Blut mittels Venenpunktur unter sauberen Bedingungen entnehmen.
2. Sofort 9 Teile Blut mit einem Teil 3,2% Natriumzitrat (0,105M) gut mischen.
3. Probe bei 1500g 10 Minuten lang zentrifugieren (Thrombozyten <10000µl)
4. Plasma nach der Zentrifugierung entfernen und in einem Röhrchen aus Plastik oder silikonisierten Glas aufbewahren.
5. Plasma innerhalb von 4 Stunden verwenden, andernfalls gefroren lagern und kurz vor Gebrauch auftauen.

Verfahren

A. Automatenmethode: Coatron A

Fibrinogen		A4		A6	
PAT	Patient	10µl	CP1	10µl	CP1
BUF	IBS Buffer	90µl	P39	90µl	P79
CLR	-	0µl	-	0µl	-
DP	-	0µl	P00	0µl	P00
R0	-	0µl	P00	0µl	P00
R1	-	0µl	P00	0µl	P00
R2	Fibrinogen	50µl	P29	50µl	P49

	A4	A6
Incubation	0s	
Maxtime	120s	
Unit	769	
Method	Coag	
Math	log XY	
CT-Mech	Yes	
Deadtime	3s	

	A4	A6
SENS	0	
POINTS	4	
MIX	No	
Clean	1	3
Multi	1	1
S-Corr	0%	
T-Corr	0%	

B. Manuelle Methode: Coatron M

1. Vorbereitung von Standard-, Kontroll- und Patientenlösungen

Standardlösung	Plasma	IBS Puffer
1:5	200µL Standard	800µL
1:10	500µL 1:5 STD	500µL
1:20	500µL 1:10 STD	500µL
1:40	500µL 1:20 STD	500µL
Patient oder Kontrolle	100µL Plasma	900µL

2. 50µl verdünntes Standard- oder Patientenplasma (1:10) in eine Küvette pipettieren. Bei 37°C für 1-2 Minuten erwärmen
3. 25µl Thrombinreagenz hinzufügen und gleichzeitig Test starten.

Wenn Sie ein anderes Gerät verwenden, lesen Sie bitte für genauere Informationen die entsprechende Geräteanleitung.

Kalibrierung

TECal Normal oder anderes kommerzielles Standardplasma, mit bekanntem Fibrinogengehalt, sollte als Referenz (200-300 mg/dl) verwendet werden. Geben Sie die Gerinnungszeit jeder FIB Standard Lösung auf der Y- Achse gegen die FIB Konzentration (mg/dl) auf der X- Achse an. Verwenden Sie Millimeterpapier. Die Reihe der besten Ergebnisse sollte durch lineare Regressionsanalyse bestimmt werden. Fibrinogen in den Plasmaproben kann durch Interpolation der Kalibrierungskurve bestimmt werden.

Erwartete Ergebnisse

Typische normale Ergebnisse sind 180-450mg/dl[4,5]. Die Ergebnisse sind jedoch von der Methode, wie die Gerinnungszeit bestimmt wird, abhängig und können von Labor zu Labor variieren. Jedem Labor wird empfohlen, seinen
eigenen normalen Ergebnisbereich auf dem verwendeten Instrument zu erstellen.

Qualitätskontrolle

TEControl oder anderes kommerzielles Kontrollplasma sollte, um eine gute Qualität sicherzustellen, in regelmäßigen Abständen entsprechend Laborrichtlinien gemessen werden. in regelmäßigen Abständen entsprechend Laborrichtlinien gemessen werden. TEControl kann einmalig wieder eingefroren werden. Hierfür 120-150µL in einem verschließbaren polypropylen Gefäß bei -20°C aufbewahren und innerhalb der nächsten 30 Tage verwenden.

Beschränkungen

A. Probenvorbereitung. Achten Sie auf:
1. nur Plastikröhrchen oder silikonisiertes Glas verwenden
2. verzögertes Mischen von Blut mit Antikoagulanz vermeiden
3. Kontaminierung mit Gewebethromboplastin vermeiden
4. falsches Verhältnis von Antikoagulanz und Blut vermeiden
5. Hämolytische,lipämische oder ikterische Proben können optische Systeme stören

B. Labortechniken
1. Tests bei 37°C durchführen
2. nur hochreines Wasser verwenden
3. der optimale pH Wert ist 7,0-7,5

Leistungsdaten

Präzision:	VK% (Einzellauf)	VK% (Mehrfachlauf)
Normale Kontrolle	< 5.0	< 5.0
Abnormale Kontrolle	< 5.0	< 10.0

(Typische Leistung beim Gerät Coatron M4)

Garantie

Es wird garantiert, dass die Wirkungsweise dieses Produktes den Angaben auf der Packung und in der Produktliteratur entspricht. TECO haftet weder für die Verkäuflichkeit oder Eignung dieses Produktes für irgendwelche andere Zwecke noch für irgendwelche Folgeschäden, die sich aus der vorstehenden, expliziten Garantie ergeben.

Referenzen

1. Clauss, A., Gerinnungsphysiologische Schnellmethode zur bestimmung des Fibrinogens. Acta Haematol., 1957, 17: 237-246.
2. Shaw, T.S.,Assays for Fibrinogen and its Derivatives, CRC Crit. Rev. Clin. Lab. Sci., 1977, 8: 145-192.
3. National Committee for the National Laboratory (NCCLS) Standards: Collection transport and preparation of blood specimens for coagulation testing and performance of coagulation assays. Document H21-A2, vol. 11, No. 23, 1991.
4. Scully, R.E. et al., Normal Reference Laboratory Values, N. Eng. J. Med., 1980, 302(37) : 37-48.
5. Okuno, T. and Selenko, V., Amer. J. Med. Tech., 1972, 38(6) : 196-201.

Erklärung der Symbole:

	Verfallsdatum	IVD	In-Vitro Diagnostik		Biologische Gefahr	REF	Katalog-Nummer		Begleitpapiere beachten
	Bei 2-8°C lagern	CE	EU Konformität		Hersteller	LOT	Lot. – Nummer	EC REP	Bevollmächtigter

Revisions-Übersicht:

Rev.	am	Änderung durch	Gültig für	Freigabe am	Freigabe durch
1	5.4.11	WG	Technoclone FIB		
	Beschreibung:	New box insert for Technoclone FIB.			
2	21.12.11	CB	Technoclone FIB	21.12.11	CH
	Beschreibung:	Neue Stabilitätsangaben. Die Vorgaben wurden dem Technoclone Stability Test Report „TC6E0C.01“ vom 5.5.2010 entnommen.			
3	11.11.13	CB	Technoclone FIB		
	Beschreibung:	- Protokoll für A4+A6 - Stabilitätsdaten neu			
4	16.10.17	AR	Technoclone FIB	16.10.17	CH
	Beschreibung:	Technoclone Puffer (A0591-090) wird ersetzt durch IBS (A0590-125) (wegen deutlicher Messunterschiede bei Coatron A und X Serie) Werteermittlung für das CoA erfolgt ebenso mit IBS (A0590-125)			
5	23.01.18	VG	Technoclone FIB	23.01.18	VG
	Beschreibung:	Neue Stabilitätsangaben von Technoclone vom Thrombin Reagent.			

IBS Buffer

CE IVD REF ***A0590-125***

Intended Use
The IBS Buffer solution is optimally formulated for use on Coagulation Analyzers. Use in accordance with the recommended Operators Manuals for installing and replacing Owrens Veronal Buffer (OVB). The IBS can be used as the diluent for preparing plasma dilutions in the performance of Fibrinogen determinations and Coagulation Factor Assays with all manual, mechanical, or photo-optical means of clot detection. Follow Reagent manufacturer's recommended procedures for preparation of plasma dilutions using Imidazole Buffered Saline.

Contents & Determinations

Product	IBS Buffer
Cat.No.	A0590-125
IBS Buffer	1x125 mL

Preparation
IBS: pH 7.3 - 7.4, liquid
Ready to use.

Storage and Stability
Unopened reagents are stable until the expiration date shown on the label stored at 2-8°C.

Precautions
Avoid contact with skin and eyes. Wear suitable protective clothing. Dispose components in compliance with local regulations for infectious material.

Warranty
This product is warranted to perform in accordance with its labelling and literature. TECO disclaims any implied warranty of merchantability or fitness for any other purpose, and in no event will TECO be liable for any consequential damages arising out of aforesaid express warranty.

Symbols key:

	Expiry date	IVD	In Vitro Diagnostica		Biological hazard	REF	Catalogue Number		Consult accompanying documents
	Store at 2-8°C	CE	EU conformity		Manufacturer	LOT	Lot. Number	EC REP	Authorized Representative

IBS Buffer

IVD REF *A0590-125*

Verwendungszweck

Die IBS Pufferlösung (Imidazole Buffered Saline) wird für die Verdünnung von Plasma verwendet werden, wie es z.B. bei der koagulometrischen Bestimmung von Fibrinogen, Einzelfaktoren oder auch Verdünnungsreihen für die Methoden Kalibrierung notwendig ist.

Inhalte und Bestimmungen

Produkt	IBS Puffer
Kat.Nr.	A0590-125
IBS Buffer	1x125 mL

Vorbereitung

IBS: pH 7.3 - 7.4, flüssig
Gebrauchsfertig

Lagerung und Stabilität

Ungeöffnete Reagenzien sind bei Lagerung zwischen 2-8°C bis zum auf dem Etikett angegebenen Verfallsdatum haltbar.

Vorsichtsmaßnahmen

Haut- und Augenkontakt vermeiden. Angemessene Schutzkleidung tragen. Bestandteile gemäß lokaler Vorschriften für infektiöse Materialien entsorgen.

Garantie

Es wird garantiert, dass die Wirkungsweise dieses Produktes den Angaben auf der Packung und in der Produktliteratur entspricht. TECO haftet weder für die Verkäuflichkeit oder Eignung dieses Produktes für irgendwelche andere Zwecke noch für irgendwelche Folgeschäden, die sich aus der vorstehenden, expliziten Garantie ergeben.

Erklärung der Symbole:

	Verfallsdatum	IVD	In-Vitro Diagnostik		Biologische Gefahr	REF	Katalog-Nummer		Begleitpapiere beachten
	Bei 2-8°C lagern	CE	EU Konformität		Hersteller	LOT	Lot. – Nummer	EC REP	Bevollmächtigter

TEClot APTT-S

CE IVD REF **A0320-050**

Intended Use
Clotting test for quantitative determination of the Activated Partial Thromboplastin Time (APTT) in citrated human plasma using silicate as contact activator for factor XII. Intended to be used by professional laboratory personnel using coagulation analysers. The determination of the APTT is used for the global evaluation of the intrinsic pathway and detecting deficiencies of the intrinsic coagulation factors VIII, IX, XI, XII, and Fletcher Factor or other coagulation methods where an APTT reagent is required[1,2].

The APTT reagent in the kit contains phospholipids and silica to ensure a highly consistent and stable product[3]. The APTT reagent is lupus anticoagulant insensitive. Lupus anticoagulant insensitive reagents yield more reliable factor assay results than reagents, which are sensitive to lupus inhibitors[4].

Prolonged clotting times maybe observed in the following situations: deficiency of intrinsic coagulation factors, presence of heparin or other anticoagulants, which affect the intrinsic pathway and in liver diseases.

Contents

Product	TEClot aPTT-S
REF	A0320-050
aPTT-S reagent	10x5 mL
Determinations*	2000

*Micro method (75µL in total)

APTT-S reagent contains colloidal silicate with phospholipids, buffer and preservatives.

Recommended additional material (not included in package)

Auxilary reagents	A0350-050 Calcium Chloride 0.025M, 10 x 5mL
Calibration	not required
Quality Control	P6001-010 TEControl N, 10 x 1mL P6101-010 TEControl A, 10 x 1mL

Preparation
Ready to use. Swirl APTT reagent gently prior usage

Storage & Stability
Unopened reagents are stable until the expiration date shown on the label stored at 2°-8°C. Opened reagent:

	2-8 °C	20-25 °C	37 °C
APTT-S Reagent	30 days	8 days	8 hours

Precautions
The reagent contains sodium azide (less than 0.1%) to prevent microbial growth. Avoid contact with skin and eyes. Wear suitable protective clothing. Dispose components in compliance with local regulations for infectious material.

Specimen collection and storage[5]
1. Obtain venous blood by clean vein puncture.
2. Immediately mix 9 parts blood with 1 part 3.2% sodium citrate (0.105M) and mix well
3. Centrifuge the specimen at 1500g for 10 min. (platelet < 10000/µL)
4. Separate plasma after centrifugation and store in plastic or siliconised glass tube.
5. Use plasma within 4 hours, otherwise store frozen and thaw just prior to use.

Stability of plasma: 4h at 18-26°C 8h at 2-8° 14d at -20°C 6m at -70°C

Procedure
A. Automated Method: Coatron A
See application book of device

B. Manual Method: Coatron X
1. Prewarm **$CaCl_2$** (0.025M) at 37°C for at least 10 min
2. Pipette **25 µl of sample** into a test cuvette. Prewarm at 37°C for 1-2 minutes.
3. Add **25 µl APTT-S reagent** and incubate exactly for **3 min** at 37°C.
4. Add **25 µl of $CaCl_2$** (0.025M) and simultaneously start test.
5. Record the clotting time in seconds.

Expected Results
Typical normal results are 27-42 sec. However results are influenced by the method of clot detection and can vary from laboratory to laboratory. Each laboratory is recommended to establish its own normal range on the specific instrument used.

Quality Control
TEControl or other commercial control plasma should be used for reliable quality control of performance at a frequency in accordance with good laboratory practice (GLP). TEControl can be frozen one time after reconstitution. 120-150 µl stored in closed polypropylen tubes at -20°C is stable for 30 days

Limitations
A. Specimen Collection. AVOID:
1. Use only plastic tubes or siliconised glass.
2. Delayed mixing of blood with anticoagulant.
3. Contamination with tissue thromboplastin.
4. Improper ratio of anticoagulant with blood.
5. Hemolyzed, icteric or lipemic samples may interfere optical systems

B. Laboratory Techniques
1. Perform tests at 37°C.
2. Use only high purity water.
3. Optimum pH is 7.0-7.5.

C. Interfering substances
1. Bilirubin 40mg/dL
2. Haemoglobin 1000 mg/dL

Performance Characteristics
Typical performance on instrument Coatron X

Precision:	CV% (within run)	CV% (inter-runs)
QC control	< 3,0	< 5,0

Factor & Heparin sensitivity:

	APTT Clotting time (s)		
Factor (%)	F VIII	F IX	F XI
< 1%	100	80	103
10%	53	52	58
40%	40	39	41
100%	35	35	358

Heparin (U/mL)	0 U/mL	0,2 U/mL	0,4 U/mL
APTT clotting time (s)	35	70	180

These values should be used as guidelines only. Each laboratory should establish factor or heparin sensitivity using its own instruments and techniques.

Warranty
This product is warranted to perform in accordance with its labelling and literature. TECO disclaims any implied warranty of merchantability or fitness for any other purpose, and in no event will TECO be liable for any consequential damages arising out of aforesaid express warranty.

References

1. Proctor RR, Rapaport SI. The partial thromboplastin time with kaolin. A simple screening test for first stage plasma clotting factor deficiencies. *Am J Clin Pathol 36, 212-219 (1961).*
2. Triplett DA, Harms CS, Koepke JA. The effect of heparin on the activated partial thromboplastin time. *Am J Clin Pathol 70, 556-569 (1978).*
3. Stevenson KJ, Easton AC, Thomson JM, Poller L. The reliability of activated partial thromboplastin time methods and the relationship to lipid composition and ultrastructure. *Thromb Haemost 55, 250-258 (1986).*
4. Denis-Magdelaine A, Flahault A, Verdy E. Sensitivity of sixteen APTT reagents for the presence of lupus anticoagulants. *Haemostasis 25, 98-105 (1995).*
5. NCCLS: Guidelines for the Standardized Collection, Transport and Preparation of Blood Specimens for Coagulation Testing and Performance of Coagulation Assays

Symbols key:

	Expiry date	IVD	In Vitro Diagnostica		Biological hazard	REF	Catalogue Number		Consult accompanying documents
	Store at 2-8°C	CE	EU conformity		Manufacturer	LOT	Lot. Number	EC REP	Authorized Representative

TECO Medical Instruments Production + Trading GmbH, Dieselstr. 1 - 84088 Neufahrn i.NB - Germany

TEClot APTT-S

CE | IVD | REF A0320-050

Verwendungszweck

Dieses Produkt ist bestimmt für die quantitative Bestimmung der aktivierten partiellen Thromboplastinzeit (APTT) in humanen Citratplasma mit Hilfe von Silikat als Kontaktaktivator für Faktor XII. Die Anwendung ist bestimmt für medizinisches Fachpersonal und benötigt einen Gerinnungsanalyser.

Die Bestimmung der APTT dient der globalen Auswertung des intrinsischen Gerinnungssystems, sowohl zum Nachweis von Mängeln bei den intrinsischen Koagulationsfaktoren VIII, IX, XI, XII und Fletcher Faktor oder anderer Koagulationsmethoden, bei denen ein APTT - Reagenz benötigt wird.[1,2]

Das APTT Reagenz in diesem Kit enthält Phospholipide und Silizium, um ein sehr widerstandsfähiges und stabiles Produkt zu gewährleisten[3]. Das Reagenz reagiert nicht auf Lupus Antikoagulanz und liefert daher verlässlichere Ergebnisse bei Faktorbestimmungen[4]. Verlängerte Gerinnungszeiten können bei den folgenden Situationen beobachtet werden: Mangel an intrinsischen Koagulationsfaktoren, Vorhandensein von Heparin oder andere Antikoagulantien, die das intrinsische System beeinflussen und bei Lebererkrankungen.

Inhalt

Produkt	TEClot aPTT-S
REF	A0320-050
aPTT-S Reagenz	10x5 mL
Bestimmungen*	2000

*Micro Methode (75µL insgesamt)

Das APTT-S Reagenz enthält kolloidales Silikat mit Phospholipiden, Puffer und Konservierungsstoffe.

Zusätzlich notwendige Reagenzien (nicht in der Packung vorhanden)

Hilfsreagenzien	A0350-050 Calcium Chloride 0.025M, 10 x 5mL
Kalibration	Nicht notwendig
Qualitätskontrolle	P6001-010 TEControl N, 10 x 1mL P6101-010 TEControl A, 10 x 1mL

Vorbereitung

Das Reagenz ist gebrauchsfertig und muss vor dem Gebrauch leicht aufgemischt werden.

Lagerung und Stabilität

Ungeöffnete Reagenzien sind bei Lagerung zwischen 2-8°C bis zum auf dem Etikett angegebenen Verfallsdatum stabil. Geöffnetes Reagenz:

	2-8 °C	20-25 °C	37°C
APTT-S Reagenz	30 Tage	8 Tage	8 Stunden

Vorsichtsmaßnahmen

Das Reagenz beinhaltet Natriumazid (< 0.1%). Augen und Hautkontakt vermeiden. Geeignete Schutzkleidung tragen. Abfall gemäß lokaler Bestimmungen für infektiöse Materialien entsorgen.

Probenentnahme und Lagerung [5]

1. Venöses Blut mittels Venenpunktur unter sauberen Bedingungen entnehmen.
2. Sofort 9 Teile Blut mit einem Teil 3,2% Natriumzitrat (0,105M) gut mischen.
3. Probe bei 1500g 10Minuten lang zentrifugieren (Thrombozyten <10000µl)
4. Plasma nach der Zentrifugierung entfernen und in einem Röhrchen aus Plastik oder silikonisierten Glas aufbewahren.
5. Plasma innerhalb von 4 Stunden verwenden, andernfalls gefroren lagern und kurz vor Gebrauch auftauen.

Stabilität von Plasma: 4h bei 18-26°C 8h bei 2-8° 14d bei -20°C 6m bei -70°C

Verfahren

A. Automatenmethode: Coatron A
Siehe Applikationsbuch des Gerätes

B. Manuelle Methode: Coatron X

1. Kalciumchlorid (0,025M) mind. 10 Minuten lang bei 37°C erwärmen.
2. **25µl Probe** in eine Küvette pipettieren. Bei 37°C für 1-2 min vorwärmen.
3. **25µl APTT-S** Reagenz hinzufügen und für genau **3 min bei 37°C inkubieren**
4. **25µl $CaCl_2$** (0,025M) hinzufügen und gleichzeitig Test starten.
5. Gerinnungszeit in Sekunden notieren.

Erwartete Ergebnisse

Typische normale Ergebnisse liegen bei 27-42 Sekunden. Jedoch sind die Ergebnisse von der verwendeten Methode der Gerinnungsbestimmung abhängig und können in verschiedenen Labors unterschiedlich ausfallen. Jedem Labor wird empfohlen, eine eigene Ergebnisreihe und den Normalbereich mit dem verwendeten Gerät zu erstellen.

Qualitätskontrolle

TEControl oder anderes kommerzielles Kontrollplasma sollte in regelmäßigen Abständen entsprechend Laborrichtlinien gemessen werden. TEControl kann einmalig wieder eingefroren werden. Hierfür 120-150µL in einem verschließbaren polypropylen Gefäß bei -20°C aufbewahren und innerhalb der nächsten 30 Tage verwenden.

Vorschriften

A. Probenvorbereitung. Achten Sie auf:
1. nur Plastikröhrchen oder silikonisiertes Glas verwenden
2. verzögertes Mischen von Blut mit Antikoagulanz vermeiden
3. Kontaminierung mit Gewebethromboplastin vermeiden
4. falsches Verhältnis von Antikoagulanz und Blut vermeiden
5. Hämolytische,lipämische oder ikterische Proben können optische Systeme stören

B. Labortechniken
1. Tests bei 37°C durchführen
2. nur hochreines Wasser verwenden
3. der optimale pH Wert ist 7,0-7,5

C. Interferenzen
1. Bilirubin: kein Effekt unter 40mg/dL
2. Hämoglobin: kein Effekt unter 1000mg/dL

Leistungsdaten

Typische Leistungsdaten beim Gerät Coatron X

Präzision:	VK% (Einzellauf)	CV% (Mehrfachlauf)
QC control	< 3,0	< 5,0

Faktor & Heparin Empfindlichkeit:

	APTT Gerinnungszeit (s)		
Faktor (%)	F VIII	F IX	F XI
< 1%	100	80	103
10%	53	52	58
40%	40	39	41
100%	35	35	358

Heparin (U/mL)	0 U/mL	0,2 U/mL	0,4 U/mL
APTT Gerinnungszeit	35	70	180

Diese Werte sollen nur als Richtlinien verwendet werden. Jedes Labor sollte mit eigenen Instrumenten und Techniken Sensitivitätswerte erstellen.

Garantie

Es wird garantiert, dass die Wirkungsweise dieses Produktes den Angaben auf der Packung und in der Produktliteratur entspricht. TECO haftet weder für die Verkäuflichkeit oder Eignung dieses Produktes für irgendwelche andere Zwecke noch für irgendwelche Folgeschäden, die sich aus der vorstehenden, expliziten Garantie ergeben.

Referenzen

1. Proctor RR, Rapaport SI. The partial thromboplastin time with kaolin. A simple screening test for first stage plasma clotting factor deficiencies. *Am J Clin Pathol 36, 212-219 (1961).*
2. Triplett DA, Harms CS, Koepke JA. The effect of heparin on the activated partial thromboplastin time. *Am J Clin Pathol 70, 556-569 (1978).*
3. Stevenson KJ, Easton AC, Thomson JM, Poller L. The reliability of activated partial thromboplastin time methods and the relationship to lipid composition and ultrastructure. *Thromb Haemost 55, 250-258 (1986).*
4. Denis-Magdelaine A, Flahault A, Verdy E. Sensitivity of sixteen APTT reagents for the presence of lupus anticoagulants. *Haemostasis 25, 98-105 (1995).*
5. NCCLS: Guidelines for the Standardized Collection, Transport and Preparation of Blood Specimens for Coagulation Testing and Performance of Coagulation Assays

Erklärung der Symbole:

Verfallsdatum	IVD	In-Vitro Diagnostik		Biologische Gefahr	REF	Katalog-Nummer	Begleitpapiere beachten

TECO Medical Instruments Production + Trading GmbH, Dieselstr. 1 - 84088 Neufahrn i.NB - Germany

TEControl N

CE IVD REF **P6001-010**

Intended Use
Use as a normal control for following coagulation tests:

PT, APTT, Thrombintime, Fibrinogen, Antithrombin and D-Dimer

Contents
10 x 1mL freeze dried citrate-anticoagulated human plasma

Preparation
Reconstitute individual vials with **1,0 ml** distilled water. Allow to stand at room temperature, with occasional swirling, for 15 min before use. Be certain all particulate matter is well dissolved.

PT whole blood (TEClot PT-B): Reconstitute individual vials with **1,7 ml** distilled water.

Storage & Stability
Unopened vials are stable until the expiration date shown on the label stored at 2°-8°C.

Dissolved plasma change analytic levels below 10% if stored as following:

-20 °C	2-8 °C	20-25 °C
1 month	8 hours	4 hours

Dissolved plasma can be refrozen only one time in aliquots (120-150µL). Stored at -20°C in closed polypropylene tubes, the aliquots must be used within 30 days.

Precautions
This product contains substance from human origin!
Avoid contact with skin and eyes. Wear suitable protective clothing. Dispose components in compliance with local regulations for infectious material. All components are checked for HIV, HBV and HCV. However products from human blood should be considered as potentially infectious.

Expected Results
Refer to "Certificate of Analysis".

Warranty
This product is warranted to perform in accordance with its labelling and literature. TECO disclaims any implied warranty of merchantability or fitness for any other purpose, and in no event will TECO be liable for any consequential damages arising out of aforesaid express warranty.

Symbols key:

Expiry date		IVD	In Vitro Diagnostica		Biological hazard		REF	Catalogue Number	Consult accompanying documents
Store at 2-8°C		CE	EU conformity		Manufacturer		LOT	Lot. Number	EC REP	Authorized Representative

TECO Medical Instruents Production + Trading GmbH, Dieselstr. 1, 84088 Neufahrn i.NB Germany

TEControl N

CE IVD REF P6001-010

Verwendungszweck
Als normale Kontrolle für folgende Gerinnungstests verwenden:

PT, APTT, Thrombinzeit , Fibrinogen, Antithrombin und D-Dimer

Inhalt
10 x 1mL gefriergetrocknetes mit Zitrat versetztes gerinnungshemmendes Humanplasma

Vorbereitung
Die einzelnen Fläschchen mit 1,0ml destilliertem Wasser anlösen. Fläschchen bei Raumtemperatur bis zur Anwendung unter gelegentlichen Verwirbeln 15 Minuten lang stehen lassen. Stellen Sie sicher, dass alle Partikel gut aufgelöst sind.

Vollblut PT (TEClot PT-B): einzelne Fläschchen mit 1,7ml destilliertem Wasser anlösen.

Lagerung und Stabilität
Ungeöffnete Fläschchen sind bei Lagerung zwischen 2-8°C zum bis auf dem Etikett angegebenen Verfallsdatum haltbar.

Gelöstes Plasma verändern die analytischen Levels unter 10% wenn wie folgt gelagert:

-20 °C	2-8 °C	20-25 °C
1 Monat	8 Stunden	4 Stunden

Gelöstes Plasma kann einmalig wiedereingefroren werden. Die Aliquots (120-150µL) sind 30 Tage haltbar, wenn sie in polypropylen Gefäßen bei -20°C aufbewahrt werden.

Vorsichtsmaßnahmen
Dieses Produkt enthält Substanzen humanen Ursprungs!
Haut- und Augenkontakt vermeiden. Angemessene Schutzkleidung tragen. Abfälle laut lokaler Regelungen für infektiöse Materialien entsorgen. Alle Bestandteile wurden auf HIV, HBV und HCV getestet. Trotzdem müssen Produkte aus menschlichem Blut immer als potentiell infektiös angesehen werden.

Erwartete Ergebnisse
Lesen Sie das Analysenzertifikat

Garantie
Es wird garantiert, dass die Wirkungsweise dieses Produkts den Angaben auf der Packung und in der Produktliteratur entspricht. TECO haftet weder für die Verkäuflichkeit oder Eignung dieses Produktes für irgendwelche andere Zwecke noch für irgendwelche Folgeschäden, die sich aus der vorstehenden, expliziten Garantie ergeben.

Erklärung der Symbole:

	Verfallsdatum	IVD	In-Vitro Diagnostik		Biologische Gefahr	REF	Katalog-Nummer		Begleitpapiere beachten
	Bei 2-8°C lagern	CE	EU Konformität		Hersteller	LOT	Lot. – Nummer	EC REP	Bevollmächtigter

TEControl A

CE IVD REF P6101-010

Intended Use
Use as an abnormal control for following coagulation tests:

PT, APTT, Thrombintime, Fibrinogen, Antithrombin and D-Dimer

Contents
10 x 1mL freeze dried citrate-anticoagulated human plasma

Preparation
Reconstitute individual vials with **1,0 ml** distilled water. Allow to stand at room temperature, with occasional swirling, for 15 min before use. Be certain all particulate matter is well dissolved.

PT whole blood (TEClot PT-B): Reconstitute individual vials with **1,7 ml** distilled water.

Storage & Stability
Unopened vials are stable until the expiration date shown on the label stored at 2°-8°C.

Dissolved plasma change analytic levels below 10% if stored as following:

-20 °C	2-8 °C	20-25 °C
1 month	8 hours	4 hours

Dissolved plasma can be refrozen only one time in aliquots (120-150µL). Stored at -20°C in closed polypropylene tubes, the aliquots must be used within 30 days.

Precautions
This product contains substance from human origin!
Avoid contact with skin and eyes. Wear suitable protective clothing. Dispose components in compliance with local regulations for infectious material. All components are checked for HIV, HBV and HCV. However products from human blood should be considered as potentially infectious.

Expected Results
Refer to "Certificate of Analysis".

Warranty
This product is warranted to perform in accordance with its labelling and literature. TECO disclaims any implied warranty of merchantability or fitness for any other purpose, and in no event will TECO be liable for any consequential damages arising out of aforesaid express warranty.

Symbols key:

Expiry date	IVD	In Vitro Diagnostica		Biological hazard	REF	Catalogue Number		Consult accompanying documents
Store at 2-8°C	CE	EU conformity		Manufacturer	LOT	Lot. Number	EC REP	Authorized Representative

TEControl A

CE IVD REF P6101-010

Verwendungszweck
Als abnormale Kontrolle für folgende Gerinnungstests verwenden:

PT, APTT, Thrombinzeit, Fibrinogen,
Antithrombin und D-Dimer

Inhalt
10 x 1mL gefriergetrocknetes mit Zitrat versetztes gerinnungshemmendes Humanplasma

Vorbereitung
Die einzelnen Fläschchen mit 1,0ml destilliertem Wasser anlösen. Fläschchen bei Raumtemperatur bis zur Anwendung unter gelegentlichen Verwirbeln 15 Minuten lang stehen lassen. Stellen Sie sicher, dass alle Partikel gut aufgelöst sind.

Vollblut PT (TEClot PT-B): einzelne Fläschchen mit 1,7ml destilliertem Wasser anlösen.

Lagerung und Stabilität
Ungeöffnete Fläschchen sind bei Lagerung zwischen 2-8°C zum bis auf dem Etikett angegebenen Verfallsdatum haltbar.

Gelöstes Plasma verändern die analytischen Levels unter 10% wenn wie folgt gelagert:

-20 °C	2-8 °C	20-25 °C
1 Monat	8 Stunden	4 Stunden

Gelöstes Plasma kann einmalig wiedereingefroren werden. Die Aliquots (120-150µL) sind 30 Tage haltbar, wenn sie in polypropylen Gefäßen bei -20°C aufbewahrt werden.

Vorsichtsmaßnahmen
Dieses Produkt enthält Substanzen humanen Ursprungs!
Haut- und Augenkontakt vermeiden. Angemessene Schutzkleidung tragen. Abfälle laut lokaler Regelungen für infektiöse Materialien entsorgen. Alle Bestandteile wurden auf HIV, HBV und HCV getestet. Trotzdem müssen Produkte aus menschlichem Blut immer als potentiell infektiös angesehen werden.

Erwartete Ergebnisse
Lesen Sie das Analysenzertifikat

Garantie
Es wird garantiert, dass die Wirkungsweise dieses Produkts den Angaben auf der Packung und in der Produktliteratur entspricht. TECO haftet weder für die Verkäuflichkeit oder Eignung dieses Produktes für irgendwelche andere Zwecke noch für irgendwelche Folgeschäden, die sich aus der vorstehenden, expliziten Garantie ergeben.

Erklärung der Symbole:

	Verfallsdatum	IVD	In-Vitro Diagnostik		Biologische Gefahr	REF	Katalog-Nummer		Begleitpapiere beachten
	Bei 2-8°C lagern	CE	EU Konformität		Hersteller	LOT	Lot. – Nummer	EC REP	Bevollmächtigter

TECal N

IVD | REF P8001-005

Intended Use
Use as a calibrator or normal control for following coagulation tests:

PT, APTT, Thrombintime, Fibrinogen,
Factors: II, V, VII, VIII, IX, X, XI, XII,
Antithrombin, Protein-C, free Protein-S,
D-Dimer

Contents
5 x 1mL freeze dried citrate-anticoagulated human plasma

Preparation
Reconstitute individual vials with **1,0 ml** distilled water. Allow to stand at room temperature, with occasional swirling, for 15 min before use. Be certain all particulate matter is well dissolved.

PT whole blood (TEClot PT-B CAT=A0260 xxx): Reconstitute individual vials with **1,7 ml** distilled water.

Storage & Stability
Unopened vials are stable until the expiration date shown on the label stored at 2°-8°C.

Dissolved plasma change analytic levels below 10% if stored as following:

-20 °C	2-8 °C	20-25 °C	37°C
30 days	24h	8h	2 hours

Dissolved plasma can be refrozen only one time in aliquots (120-150µL). Stored at -20°C in closed polypropylene tubes, the aliquots must be used within 30 days.

Precautions: Potential Biohazardous material
This product contains substance from human origin! Avoid contact with skin and eyes. Wear suitable protective clothing. Dispose components in compliance with local regulations for infectious material. All components are checked for HIV, HBV and HCV. However products from human blood should be considered as potentially infectious.

Performance Characteristics:
Refer to "Certificate of Analysis".

Limitations:
The control plasma is subject to the limitations of the assay system (reagent + instrument). Results out of expected range may indicate deterioration, false test calibration or problems with one or more components of the test system

Warranty
This product is warranted to perform in accordance with its labelling and literature. TECO disclaims any implied warranty of merchantability or fitness for any other purpose, and in no event will TECO be liable for any consequential damages arising out of aforesaid express warranty.

Symbols key:

Expiry date	IVD	In Vitro Diagnostica		Biological hazard	REF	Catalogue Number		Consult accompanying documents
Store at 2-8°C	CE	EU conformity		Manufacturer	LOT	Lot. Number	EC REP	Authorized Representative

TECal N

CE | IVD | REF P8001-005

Verwendungszweck
Als Kalibrator oder Normalkontrolle für folgende Gerinnungstests verwenden:

PT, APTT, Thrombinzeit, Fibrinogen,
Faktoren: II, V, VII, VIII, IX, X, XI, XII,
Antithrombin, Protein-C, freies Protein-S,
D-Dimer

Inhalt
5 x 1mL gefriergetrocknetes mit Zitrat versetztes gerinnungshemmendes Humanplasma

Vorbereitung
Die einzelnen Fläschchen mit 1,0ml destilliertem Wasser anlösen. Fläschchen bei Raumtemperatur bis zur Anwendung unter gelegentlichen Verwirbeln 15 Minuten lang stehen lassen. Stellen Sie sicher, dass alle Partikel gut aufgelöst sind.

Vollblut PT (TEClot PT-B CAT=A0260 xxx): einzelne Fläschchen mit 1,7ml destilliertem Wasser anlösen.

Lagerung und Stabilität
Ungeöffnete Fläschchen sind bei Lagerung zwischen 2-8°C zum bis auf dem Etikett angegebenen Verfallsdatum haltbar.

Gelöstes Plasma verändern die analytischen Levels unter 10% wenn wie folgt gelagert:

-20 °C	2-8 °C	20-25 °C	37°C
30 Tage	24 Stunden	8 Stunden	2 Stunden

Gelöstes Plasma kann einmalig wiedereingefroren werden. Die Aliquots (120-150µL) sind 30 Tage haltbar, wenn sie in polypropylen Gefäßen bei -20°C aufbewahrt werden.

Vorsichtsmaßnahmen: Potentiell infektiöses Material
Dieses Produkt enthält Substanzen humanen Ursprungs!
Haut- und Augenkontakt vermeiden. Angemessene Schutzkleidung tragen. Abfälle laut lokaler Regelungen für infektiöse Materialien entsorgen. Alle Bestandteile wurden auf HIV, HBV und HCV getestet. Trotzdem müssen Produkte aus menschlichem Blut immer als potentiell infektiös angesehen werden.

Erwartete Ergebnisse
Lesen Sie das Analysenzertifikat

Einschränkungen:
Das Kontrollplasma unterliegt den Einschränkungen der verwendeten Reagenzien und Geräte. Ergebnisse außerhalb des Sollbereichs können verursacht werden durch abgelaufene Materiale, ungültige Methodenkalibration oder Problemen an Reagenz, Gerät oder Zubehör.

Garantie
Es wird garantiert, dass die Wirkungsweise dieses Produkts den Angaben auf der Packung und in der Produktliteratur entspricht. TECO haftet weder für die Verkäuflichkeit oder Eignung dieses Produktes für irgendwelche andere Zwecke noch für irgendwelche Folgeschäden, die sich aus der vorstehenden, expliziten Garantie ergeben.

Erklärung der Symbole:

Verfallsdatum	IVD	In-Vitro Diagnostik	Biologische Gefahr	REF	Katalog-Nummer	Begleitpapiere beachten
Bei 2-8°C lagern	CE	EU Konformität	Hersteller	LOT	Lot. – Nummer	EC REP	Bevollmächtigter